,DTH/Антиген,DTH/Качественное значение,DTH/Количественное значение до иммунизации,DTH/Количественное значение после иммунизации,ELISPOT/Антиген,ELISPOT/Качественное значение,ELISPOT/Количественное значение до иммунизации,ELISPOT/Количественное значение после иммунизации,Адъювант в составе вакцины/Значение,Антиген-специфические лимфоциты in vitro/Антиген,Антиген-специфические лимфоциты in vitro/Качественное значение,Вакцинация/ГРУППА: наибольшее значение кол-ва введенных клеток,Вакцинация/ГРУППА: наименьшее значение кол-ва введенных клеток,Вакцинация/Кол-во клеток введенных за одну вакцинацию,Вакцинация/Количество вакцинаций,Вакцинация/Общее количество введенных клеток,Возраст/ГРУППА: наибольшее значение,Возраст/ГРУППА: наименьшее значение,Возраст/Точное значение или медиана (для группы),Выживаемость/Единицы измерения,Выживаемость/Результат,Выживаемость/Срок дожития/наблюдения,Гаплотип/Значение,Диагноз/Значение,Иммунный статус до иммунизации/Значение,Индекс ECOG/ГРУППА: наибольшее значение,Индекс ECOG/ГРУППА: наименьшее значение,Индекс ECOG/Точное значение или медиана (для группы),Индекс Карновского/ГРУППА: наибольшее значение,Индекс Карновского/ГРУППА: наименьшее значение,Индекс Карновского/Точное значение или медиана (для группы),Индукторы созревания ДК/Значение,Источник дендритных клеток/Значение,Лечение до иммунизации/Значение,Объективный клинический ответ/Значение,Опухолевые маркеры/Качественное значение,Опухолевые маркеры/Количественное значение до вакцинации,Опухолевые маркеры/Количественное значение после вакцинации,Опухолевые маркеры/Тип маркера,Побочные эффекты/Значение,Пол/Значение,Раса/Значение,Сопутствующая терапия/Значение,Способ введения вакцины/Значение,Стадия заболевания/Значение,Тип вакцины/Значение
0,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
1,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
3,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,,,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
4,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Radiotherapy,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
5,,,,,,,,,KLH,Control antigen,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Radiotherapy,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
7,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
8,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Radiotherapy,Stable Desease,Decrease,,,PSA,Not significant,Male,,Immunotherapy,Intravenously,,Protein
9,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Chemotherapy,,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
11,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Surgery,,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
12,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Chemotherapy,,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
13,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14,,,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
15,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,,,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
16,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
17,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,,Stable Desease,Decrease,,,PSA,Not significant,Male,,Immunotherapy,Intravenously,,Protein
18,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Surgery,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
19,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
21,,,,,,,,,KLH,Control antigen,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
22,,,,,Tumor antigen,Yes,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Surgery,Stable Desease,Decrease,,,PSA,Not significant,Male,,Immunotherapy,Intravenously,,Protein
23,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
24,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,,,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
25,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26,,,,,,,,,None,Control antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
27,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Chemotherapy,,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
28,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Chemotherapy,Stable Desease,Decrease,,,PSA,Not significant,Male,,Immunotherapy,Intravenously,,Protein
29,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Surgery,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Protein
30,,,,,,,,,,Tumor antigen,Yes,,,,4.0,2172000.0,83.0,48.0,69.0,,,,,Prostate cancer,Normal,1.0,1.0,,,,,,Monocytes,Surgery,Stable Desease,Decrease,,,PSA,Not significant,Male,,Immunotherapy,Intravenously,,Protein
31,,,,,,,,,,,,,,,8.0,10000000.0,,,,,,,HLA-A1,Melanoma,Normal,,,,,,100.0,TNF-α,HSC,Chemotherapy,Stable Desease,,,,,Not significant,Female,,,Intravenously,,Peptide
32,,,,,,,,,,,,,,,12.0,10000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,100.0,TNF-α,HSC,Surgery,Complete response,,,,,Not significant,,,,Intravenously,,Peptide
33,Tumor antigen,Yes,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,4.0,5000000.0,,,,,,,HLA-A1,Melanoma,Normal,,,,,,100.0,TNF-α,HSC,Chemotherapy,Progressive Disease,,,,,Not significant,,,,Intravenously,,Peptide
34,Tumor antigen,Yes,,,,,,,,,,,,,7.0,5000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,,TNF-α,HSC,Chemotherapy,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Peptide
35,,,,,Tumor antigen,No,,,,,,,,,8.0,10000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,100.0,TNF-α,HSC,Chemotherapy,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Peptide
36,,,,,,,,,,Tumor antigen,No,,,,4.0,10000000.0,,,,,,,HLA-A1,Melanoma,Normal,,,,,,90.0,TNF-α,HSC,Chemotherapy,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Peptide
37,Tumor antigen,Yes,,,,,,,,,,,,,4.0,10000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,100.0,TNF-α,HSC,Surgery,Progressive Disease,,,,,Not significant,,,,Intravenously,,Peptide
38,,,,,,,,,,,,,,,8.0,10000000.0,,,,,,,HLA-A1,Melanoma,Normal,,,,,,90.0,TNF-α,HSC,Chemotherapy,Partial Response,,,,,Not significant,Male,,,Intravenously,,Peptide
39,Tumor antigen,Yes,,,Tumor antigen,No,,,,Tumor antigen,No,,,,4.0,10000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,80.0,TNF-α,HSC,Surgery,Stable Desease,,,,,Not significant,,,,Intravenously,,Peptide
40,,,,,,,,,,,,,,,8.0,10000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,100.0,TNF-α,HSC,Chemotherapy,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Peptide
41,Tumor antigen,Yes,,,,,,,,,,,,,4.0,10000000.0,,,,,,,HLA-A1,Melanoma,Normal,,,,,,90.0,TNF-α,HSC,Chemotherapy,Progressive Disease,,,,,Not significant,,,,Intravenously,,Peptide
42,Tumor antigen,Yes,,,,,,,,,,,,,4.0,50000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,100.0,TNF-α,HSC,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Peptide
43,,,,,,,,,,,,,,,4.0,50000000.0,,,,,,,HLA-A1,Melanoma,Normal,,,,,,100.0,TNF-α,HSC,Chemotherapy,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Peptide
44,Tumor antigen,Yes,,,,,,,,Tumor antigen,No,,,,4.0,50000000.0,,,,,,,HLA-A2,Melanoma,Normal,,,,,,100.0,TNF-α,HSC,Chemotherapy,Stable Desease,,,,,Not significant,,,,Intravenously,,Peptide
45,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
46,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
47,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
48,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
49,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
50,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
51,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
52,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
53,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
54,Control antigen,Yes,,,,,,,KLH,,,,,,3.0,10000000.0,17.0,3.0,16.0,,,,,Fibrosarcoma,,,,,,,,,,Chemotherapy,,,,,,Not significant,Female,,,Intradermal,Metastatic,Lysate
55,,,,,,,,,,Tumor antigen,Yes,,,,2.0,3200000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Protein
56,,,,,,,,,,,,,,,2.0,6300000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Protein
57,,,,,,,,,,,,,,,2.0,14900000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Protein
58,,,,,,,,,,,,,,,2.0,3400000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Radiotherapy,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Protein
59,,,,,,,,,,,,,,,2.0,4800000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Protein
60,,,,,,,,,,Tumor antigen,Yes,,,,2.0,17700000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Protein
61,,,,,,,,,,Tumor antigen,Yes,,,,2.0,7600000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Protein
62,,,,,,,,,,Tumor antigen,Yes,,,,2.0,14900000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Protein
63,,,,,,,,,,Tumor antigen,Yes,,,,2.0,18600000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intravenously,,Protein
64,,,,,,,,,,Tumor antigen,Yes,,,,2.0,24400000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intradermal,,Protein
65,,,,,,,,,,Tumor antigen,Yes,,,,2.0,2300000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Stable Desease,,,,,Not significant,Male,,,Intradermal,,Protein
66,,,,,,,,,,,,,,,2.0,14600000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intradermal,,Protein
67,,,,,,,,,,Tumor antigen,Yes,,,,2.0,10600000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,,Progressive Disease,,,,,Not significant,Male,,,Intradermal,,Protein
68,,,,,,,,,,Tumor antigen,Yes,,,,2.0,5100000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Radiotherapy,Progressive Disease,,,,,Not significant,Male,,,Intradermal,,Protein
69,,,,,,,,,,Tumor antigen,Yes,,,,2.0,22700000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Stable Desease,,,,,Not significant,Male,,,Intradermal,,Protein
70,,,,,,,,,,,,,,,2.0,9500000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intralymphatically,,Protein
71,,,,,,,,,,,,,,,2.0,14400000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intralymphatically,,Protein
72,,,,,,,,,,,,,,,2.0,26900000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intralymphatically,,Protein
73,,,,,,,,,,Tumor antigen,Yes,,,,2.0,2600000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Intralymphatically,,Protein
74,,,,,,,,,,Tumor antigen,Yes,,,,2.0,9700000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,,Stable Desease,,,,,Not significant,Male,,,Intralymphatically,,Protein
75,,,,,,,,,,,,,,,2.0,10300000.0,79.0,59.0,67.0,,,,,Prostate cancer,Normal,,,,100.0,90.0,100.0,,Monocytes,Surgery,Stable Desease,,,,,Not significant,Male,,,Intralymphatically,,Protein
76,Tumor antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,100000.0,,,55.0,,,,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,,
77,Tumor antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,100000.0,,,59.0,,,,,,,,,,,,,,,Surgery,Complete response,,,,,,Male,,,,,
78,Control antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,250000.0,,,43.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
79,,,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,100000.0,,,42.0,,,,,,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,Female,,,,,
80,,,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,250000.0,,,45.0,,,,,,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,Male,,,,,
81,Tumor antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,100000.0,,,36.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
82,Control antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,500000.0,,,61.0,,,,,,,,,,,,,,,Surgery,Partial Response,,,,,,Female,,,,,
83,Tumor antigen,Yes,,,Control antigen,Yes,,,,,,,,,,250000.0,,,44.0,,,,,,,,,,,,,,,Immunotherapy,Complete response,,,,,,Male,,,,,
84,Control antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,500000.0,,,50.0,,,,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
85,Tumor antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,1000000.0,,,56.0,,,,,,,,,,,,,,,Surgery,Partial Response,,,,,,Female,,,,,
86,Control antigen,Yes,,,,,,,,Tumor antigen,Yes,,,,4.0,500000.0,,,50.0,,,,HLA-A201,Melanoma,Normal,,,,,80.0,,Flt3L,HSC,Surgery,Progressive Disease,,,,,None,Male,,,Subcutaneously,Metastatic,Peptide
87,Tumor antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,1000000.0,,,43.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
88,,,,,Control antigen,Yes,,,,,,,,,,250000.0,,,73.0,,,,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,,
89,Control antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,500000.0,,,57.0,,,,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
90,Tumor antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,1000000.0,,,70.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
91,Tumor antigen,Yes,,,,,,,,Tumor antigen,Yes,,,,,100000.0,,,66.0,,,,,,,,,,,,,,,Radiotherapy,Not evaluable,,,,,,Male,,,,,
92,Control antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,1000000.0,,,40.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
93,Tumor antigen,Yes,,,Control antigen,Yes,,,,Tumor antigen,Yes,,,,,1000000.0,,,66.0,,,,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
94,Tumor antigen,Yes,,,,,,,KLH,,,,,,14.0,,,,53.0,,,,HLA-A1,Thyroid Cancer,,,,,,,,TNF-α,Monocytes,Surgery,Stable Desease,Decrease,,,-,None,Female,,,Intracutaneously,,Peptide
95,Tumor antigen,Yes,,,,,,,KLH,,,,,,14.0,,,,62.0,,,,HLA-A1,Thyroid Cancer,,,,,,,,TNF-α,Monocytes,Surgery,Stable Desease,Increase,,,-,Not significant,Male,,,Intracutaneously,,Peptide
96,Tumor antigen,Yes,,,,,,,KLH,,,,,,12.0,,,,37.0,,,,HLA-A2,Thyroid Cancer,,,,,,,,TNF-α,Monocytes,Chemotherapy,Partial Response,Increase,,,-,Not significant,Male,,,Intracutaneously,,Peptide
97,Tumor antigen,Yes,,,,,,,KLH,,,,,,10.0,,,,32.0,,,,HLA-A2,Thyroid Cancer,,,,,,,,TNF-α,Monocytes,Surgery,Stable Desease,Increase,,,-,Not significant,Female,,,Intracutaneously,,Peptide
98,Tumor antigen,Yes,,,,,,,KLH,,,,,,11.0,,,,58.0,,,,HLA-A1,Thyroid Cancer,,,,,,,,TNF-α,Monocytes,Surgery,Stable Desease,Increase,,,-,Not significant,Female,,,Intracutaneously,,Peptide
99,Tumor antigen,Yes,,,,,,,KLH,,,,,,11.0,,,,31.0,,,,HLA-A2,Thyroid Cancer,,,,,,,,TNF-α,Monocytes,Surgery,Stable Desease,Increase,,,-,Not significant,Male,,,Intracutaneously,,Peptide
100,Tumor antigen,Yes,,,,,,,KLH,,,,,,7.0,,,,38.0,,,,HLA-A2,Thyroid Cancer,,,,,,,,TNF-α,Monocytes,Surgery,Progressive Disease,Decrease,,,-,Not significant,Female,,,Intracutaneously,,Peptide
101,,,,,,,,,,Tumor antigen,Yes,,,,6.0,10000000.0,,,75.0,Months,Dead,2.0,HLA-A24,Bladder cancer,,,,,,,,,Monocytes,Surgery,Complete response,,,,,Not significant,Female,,,Subcutaneously,IV,Peptide
102,,,,,,,,,,Tumor antigen,Yes,,,,18.0,10000000.0,,,65.0,Months,Live,8.0,HLA-A2,Bladder cancer,,,,,,,,,Monocytes,Surgery,Partial Response,,,,,Not significant,Male,,,Subcutaneously,IV,Peptide
103,,,,,,,,,,Tumor antigen,Yes,,,,6.0,10000000.0,,,64.0,Months,Live,5.0,HLA-A2,Bladder cancer,,,,,,,,,Monocytes,Surgery,Partial Response,,,,,Not significant,Male,,,Subcutaneously,IV,Peptide
104,,,,,,,,,,Tumor antigen,Yes,,,,6.0,10000000.0,,,56.0,Months,Live,2.0,HLA-A2,Bladder cancer,,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,Not significant,Male,,,Subcutaneously,IV,Peptide
105,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
106,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Progressive Disease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
107,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Stable Desease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
108,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
109,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Stable Desease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
110,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Progressive Disease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
111,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
112,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Stable Desease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
113,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
114,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
115,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
116,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
117,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
118,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
119,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Stable Desease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
120,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
121,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
122,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Progressive Disease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
123,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
124,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Partial Response,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
125,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Progressive Disease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
126,,,,,,,,,,,,,,,3.0,,,,,,,,,Colon cancer,,,,,,,,,,,Progressive Disease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
127,,,,,,,,,,,,,,,3.0,,,,,,,,,Prostate cancer,,,,,,,,,,,Progressive Disease,Decrease,,,PSA,None,,,Immunotherapy,Intradermal,,Expression vector
128,Control antigen,Yes,,,,,,,KLH,,,,,,4.0,,,,50.0,,,,,Breast cancer,,,,,,,,,Monocytes,,,Increase,,,CEA,,Female,,,Intralymphatically,IV,Lysate
129,,,,,,,,,Flt3L,,,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Progressive Disease,,,,,Not significant,,,,Intravenously,Metastatic,Peptide
130,,,,,,,,,Flt3L,,,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Progressive Disease,,,,,Not significant,,,,Intravenously,Metastatic,Peptide
131,,,,,,,,,Flt3L,Tumor antigen,Yes,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Stable Desease,,,,,Not significant,Male,,,Intravenously,Metastatic,Peptide
132,,,,,,,,,Flt3L,,,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Progressive Disease,,,,,Not significant,,,,Intravenously,Metastatic,Peptide
133,,,,,,,,,Flt3L,Tumor antigen,Yes,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Complete response,,,,,Not significant,,,,Intravenously,Metastatic,Peptide
134,,,,,,,,,Flt3L,Tumor antigen,Yes,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Progressive Disease,,,,,Not significant,Male,,,Intravenously,Metastatic,Peptide
135,,,,,,,,,Flt3L,Tumor antigen,Yes,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Progressive Disease,,,,,Not significant,,,,Intravenously,Metastatic,Peptide
136,,,,,,,,,Flt3L,Tumor antigen,Yes,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Stable Desease,,,,,Not significant,,,,Intravenously,Metastatic,Peptide
137,,,,,,,,,Flt3L,,,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Progressive Disease,,,,,Not significant,Female,,,Intravenously,Metastatic,Peptide
138,,,,,,,,,Flt3L,,,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Progressive Disease,,,,,Not significant,Female,,,Intravenously,Metastatic,Peptide
139,,,,,,,,,Flt3L,Tumor antigen,Yes,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,,,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Complete response,,,,,Not significant,Male,,,Intravenously,Metastatic,Peptide
140,,,,,,,,,Flt3L,Tumor antigen,Yes,,,,2.0,10000000.0,71.0,33.0,53.0,,,,HLA-A*0201,Colon cancer,Abnormal,,,,100.0,80.0,90.0,,Monocytes,Chemotherapy,Partial Response,,,,,Not significant,,,,Intravenously,Metastatic,Peptide
141,-,Yes,,,,,,,KLH,,,,,,3.0,1000000.0,,,40.0,,,,,Melanoma,Normal,,,,,,,GM-CSF,Monocytes,Immunotherapy,Progressive Disease,,,,,,Female,,,Intradermal,IV,Lysate
142,,,,,Tumor antigen,Yes,,,,,,,,,,1000000.0,,,63.0,,,,,Melanoma,,,,,,,,,,,Partial Response,,,,,,Female,,,,,
143,,,,,,,,,,,,,,,,1000000.0,,,65.0,,,,,Melanoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
144,,,,,Tumor antigen,Yes,,,,,,,,,,1000000.0,,,55.0,,,,,Melanoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
145,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,,,1000000.0,,,66.0,,,,,Melanoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
146,,,,,,,,,,,,,,,,10000000.0,,,50.0,,,,,Colon cancer,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,,
147,Tumor antigen,Yes,,,,,,,,,,,,,,10000000.0,,,69.0,,,,,Melanoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
148,,,,,,,,,,,,,,10000000.0,,,,,73.0,,,,,Melanoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
149,,,,,,,,,,,,,,,,10000000.0,,,41.0,,,,,Melanoma,,,,,,,,,,Immunotherapy,Partial Response,,,,,,Male,,,,,
150,,,,,,,,,,,,,,,,10000000.0,,,40.0,,,,,Melanoma,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,,,
151,,,,,,,,,,,,,,,,10000000.0,,,47.0,,,,,Colon cancer,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,Male,,,,,
152,Tumor antigen,Yes,,,,,,,,,,,,,,100000000.0,,,49.0,,,,,Melanoma,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,,,
153,,,,,,,,,,,,,,,,100000000.0,,,66.0,,,,,Melanoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
154,Tumor antigen,Yes,,,,,,,,,,,,,,100000000.0,,,36.0,,,,,Glioblastoma,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,Female,,,,,
155,Tumor antigen,Yes,,,,,,,,,,,,,,52000000.0,,,50.0,,,,HLA-A24,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Female,,,,,
156,Tumor antigen,Yes,,,,,,,,,,,,,,27000000.0,,,54.0,,,,HLA-A24,,,,,,,,,,,Surgery,Progressive Disease,,,,,Not significant,Male,,,,,
157,Tumor antigen,No,,,,,,,,,,,,,,36000000.0,,,39.0,,,,HLA-A24,,,,,,,,,,,Surgery,Stable Desease,,,,,Not significant,Male,,,,,
158,,,,,,,,,,,,,,,13.0,171.7,,,53.0,Months,Dead,21.5,,,Normal,,,,,,,,,,Partial Response,,,,,Not significant,Male,,,Intravenously,,Lysate
159,,,,,,,,,,,,,,,,,,,68.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
160,-,Yes,,,,,,,,,,,,,3.0,29.1,,,57.0,Months,Dead,4.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,Intravenously,,Lysate
161,-,Yes,,,,,,,,,,,,,8.0,70.4,,,70.0,Months,Live,42.0,,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,Intravenously,,Lysate
162,-,Yes,,,,,,,,Tumor antigen,Yes,,,,12.0,61.9,,,52.0,Months,Dead,25.0,,,,,,,,,,,,Immunotherapy,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Lysate
163,,,,,,,,,,,,,,,,,,,29.0,,,,,,,,,,,,,,,,,,,,,,Female,,,,,
164,-,No,,,,,,,,,,,,,3.0,18.7,,,60.0,Months,Dead,10.4,,,,,,,,,,,,,Progressive Disease,,,,,Not significant,Female,,,Intravenously,,Peptide
165,,,,,,,,,KLH,,,,,,,,,,56.0,,,,,Renal cancer,Normal,,,,,,,,Monocytes,,,,,,,,Male,,,,,
166,-,Yes,,,,,,,KLH,,,,,,6.0,52.4,,,56.0,Months,Dead,13.5,,Renal cancer,Normal,,,,,,,,Monocytes,,Stable Desease,,,,,,Female,,,Intravenously,,Peptide
167,,,,,,,,,,,,,,,,,,,57.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
168,-,Yes,,,,,,,,Control antigen,Yes,,,,7.0,76.0,,,59.0,Months,Live,32.9,,,,,,,,,,,,,Complete response,,,,,Not significant,Male,,,Intravenously,,Lysate
169,-,Yes,,,,,,,,Tumor antigen,Yes,,,,3.0,46.6,,,57.0,Months,Dead,4.0,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Female,,,Intravenously,,Peptide
170,-,No,,,,,,,,Tumor antigen,Yes,,,,4.0,49.0,,,59.0,Months,Dead,8.8,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,Intravenously,,Peptide
171,-,Yes,,,,,,,,,,,,,3.0,39.0,,,51.0,-,-,,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,Intravenously,,Peptide
172,-,Yes,,,,,,,,,,,,,6.0,70.9,,,51.0,Months,Dead,5.0,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,Not significant,Female,,,Intravenously,,Peptide
173,-,Yes,,,,,,,,Control antigen,Yes,,,,4.0,30.9,,,52.0,Months,Live,30.0,,,,,,,,,,,,Immunotherapy,Stable Desease,,,,,,Male,,,Intravenously,,Peptide
174,,,,,,,,,,Tumor antigen,Yes,,,,,,,,49.0,,,,,,,,,,,,,,,,,,,,,,Female,,,,,
175,-,No,,,,,,,,,,,,,6.0,52.0,,,54.0,Months,Dead,8.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,Intravenously,,Peptide
176,-,No,,,,,,,,,,,,,3.0,32.0,,,57.0,,,,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Female,,,Intravenously,,Peptide
177,-,Yes,,,,,,,,,,,,,3.0,33.0,,,63.0,,,,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,Not significant,Female,,,Intravenously,,Peptide
178,,,,,,,,,,,,,,,,,,,49.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
179,-,No,,,,,,,,Control antigen,Yes,,,,3.0,31.0,,,71.0,Months,Dead,7.0,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,Intradermal,,Peptide
180,-,No,,,,,,,,,,,,,4.0,47.0,,,46.0,,,,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,Intravenously,,Peptide
181,-,Yes,,,,,,,,Control antigen,Yes,,,,3.0,29.0,,,55.0,Months,Dead,5.0,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,Intravenously,,Peptide
182,-,No,,,,,,,,Control antigen,Yes,,,,3.0,12.5,,,52.0,Months,Dead,5.0,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,Not significant,Male,,,Intradermal,,Peptide
183,Control antigen,Yes,,,,,,,,,,,,,,,,,63.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
184,-,Yes,,,,,,,,Tumor antigen,Yes,,,,3.0,9.7,,,53.0,,,,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,Intradermal,,Peptide
185,-,Yes,,,,,,,,Tumor antigen,Yes,,,,3.0,9.7,,,55.0,,,,,,,,,,,,,,,Immunotherapy,Progressive Disease,,,,,,Male,,,Intravenously,,Peptide
186,-,No,,,,,,,,Tumor antigen,Yes,,,,3.0,8.3,,,57.0,Months,Live,26.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,Intradermal,,Peptide
187,,,,,,,,,,,,,,,,,,,66.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
188,-,No,,,,,,,,,,,,,6.0,42.8,,,62.0,Months,Live,24.0,,,,,,,,,,,,Immunotherapy,Stable Desease,,,,,,Female,,,Intradermal,,Peptide
189,-,No,,,,,,,,,,,,,3.0,11.1,,,62.0,Months,Live,23.5,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,Intradermal,,Peptide
190,-,No,,,,,,,,,,,,,3.0,11.0,,,61.0,Months,Live,23.3,,,,,,,,,,,,Immunotherapy,Complete response,,,,,,Male,,,Intradermal,,Lysate
191,-,No,,,,,,,,,,,,,3.0,13.9,,,63.0,Months,Dead,5.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,Intradermal,,Lysate
192,-,No,,,,,,,KLH,,,,,,3.0,7.65,,,56.0,Months,Live,23.0,,Renal cancer,Normal,,,,,,,,Monocytes,,Progressive Disease,,,,,,Male,,,Intradermal,,Lysate
193,-,No,,,,,,,None,,,,,,,27000000.0,,,54.0,,,,HLA-A24,Rectum cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,Not significant,Female,,,,,
194,-,No,,,,,,,None,,,,,,,53000000.0,,,64.0,,,,HLA-A1,Colon cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,Not significant,Female,,,,,
195,-,No,,,,,,,None,Tumor antigen,Yes,,,,,160000000.0,,,61.0,,,,HLA-A24,Colon cancer,,,,,,,,,,Surgery,,,,,,Not significant,Female,,,,,
196,-,No,,,,,,,None,,,,,,,110000000.0,,,28.0,,,,HLA-A2,Colon cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
197,-,No,,,,,,,None,Tumor antigen,Yes,,,,,120000000.0,,,33.0,,,,HLA-A2,Stomach cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
198,-,No,,,,,,,None,Tumor antigen,No,,,,,77000000.0,,,69.0,,,,HLA-A2,Lung cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
199,-,Yes,,,,,,,None,,,,,,,85000000.0,,,57.0,,,,HLA-A24,Rectum cancer,,,,,,,,,,Surgery,Stable Desease,,,,,Not significant,Female,,,,,
200,-,No,,,,,,,None,,,,,,,65000000.0,,,56.0,,,,HLA-A2,Rectum cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
201,-,Yes,,,,,,,None,Tumor antigen,No,,,,,130000000.0,,,52.0,,,,HLA-A24,Lung cancer,,,,,,,,,,Surgery,Stable Desease,,,,,Not significant,Female,,,,,
202,-,No,,,,,,,None,,,,,,,120000000.0,,,42.0,,,,HLA-A24,Colon cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
203,-,No,,,-,Not done,,,,,,,,,2.0,1000000.0,,,50.0,,,,HLA-A2,Breast cancer,Normal,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,None,Female,,,Subcutaneously,-,Expression vector
204,-,No,,,-,-,109.0,16.0,,,,,,,3.0,1000000.0,,,48.0,,,,HLA-A2,Breast cancer,Normal,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,,Female,,,Subcutaneously,-,Expression vector
205,-,Yes,,,-,-,37.0,225.0,,,,,,,3.0,1000000.0,,,66.0,,,,HLA-A2,Breast cancer,Normal,,,,,,,,Monocytes,Surgery,Stable Desease,,,,,,Female,,,Subcutaneously,-,Expression vector
206,-,No,,,-,-,16.0,154.0,,,,,,,3.0,1000000.0,,,55.0,,,,HLA-A2,Breast cancer,Normal,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,,Female,,,Subcutaneously,-,Expression vector
207,-,No,,,-,-,266.0,874.0,,,,,,,3.0,1000000.0,,,76.0,,,,HLA-A2,Pancreatic cancer,Normal,,,,,,,,Monocytes,,Progressive Disease,,,,,,Female,,,Subcutaneously,-,Expression vector
208,-,Yes,,,-,-,41.0,85.0,,,,,,,3.0,1000000.0,,,38.0,,,,HLA-A2,Breast cancer,Normal,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,,Female,,,Subcutaneously,-,Expression vector
209,-,No,,,-,-,804.0,1002.0,,,,,,,2.0,1000000.0,,,72.0,,,,HLA-A2,Pancreatic cancer,Normal,,,,,,,,Monocytes,,Progressive Disease,,,,,,Female,,,Subcutaneously,-,Expression vector
210,-,No,,,-,-,1.0,10.0,,,,,,,3.0,1000000.0,,,66.0,,,,HLA-A2,Pancreatic cancer,Normal,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,,Male,,,Subcutaneously,-,Expression vector
211,-,Yes,,,-,-,249.0,260.0,,,,,,,3.0,1000000.0,,,46.0,,,,HLA-A2,Breast cancer,Normal,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,,Female,,,Subcutaneously,-,Expression vector
212,-,No,,,-,-,87.0,1.0,,,,,,,3.0,1000000.0,,,45.0,,,,HLA-A2,Breast cancer,Normal,,,,,,,,Monocytes,Surgery,Progressive Disease,,,,,,Female,,,Subcutaneously,-,Expression vector
213,,,,,-,Yes,,,,,,,,,,,,,69.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
214,,,,,-,Yes,,,,,,,,,,,,,59.0,,,,,,,,,,,,,,,,,,,,,,Female,,,,,
215,,,,,-,Yes,,,,,,,,,,,,,61.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
216,,,,,-,Yes,,,,,,,,,,,,,64.0,,,,,,,,,,,,,,,,,,,,,,Female,,,,,
217,,,,,Tumor antigen,Yes,,,,,,,,,,,,,61.0,,,,,,,,,,,,,,,,,,,,,,Male,,,,,
218,Tumor antigen,Yes,,,,,,,,,,,,,,10000000.0,,,47.0,-,Live,3.75,HLA-A2,Pancreatic cancer,Normal,,,,,,,,Monocytes,Chemotherapy,,,,,,Not significant,,,None,Intradermal,,RNA
219,Tumor antigen,Yes,,,,,,,,,,,,,,10000000.0,,,73.0,-,Live,3.75,HLA-A2,Pancreatic cancer,Normal,,,,,,,,Monocytes,Chemotherapy,,,,,,Not significant,,,Radiotherapy,Intradermal,,RNA
220,Tumor antigen,Yes,,,,,,,,,,,,,,10000000.0,,,53.0,-,Live,3.75,HLA-A2,Pancreatic cancer,Normal,,,,,,,,Monocytes,Chemotherapy,,,,,,Not significant,,,Radiotherapy,Intradermal,,RNA
221,-,No,,,,,,,,-,No,,,,4.0,5000000.0,,,42.0,,,,HLA-A1,Hepatocellular carcinoma,Abnormal,,,,,,,,Monocytes,,Progressive Disease,,,,,Not significant,Male,Caucasoid,,Intradermal,IV,Co-culture
222,-,-,,,,,,,,,,,,,4.0,10000000.0,,,53.0,Years,Live,3.0,HLA-A*0201,Cholangiocellular carcinoma,Normal,,,,,,,,,,Partial Response,,,,,,Male,Mongoloid,,Intradermal,,Co-culture
223,,,,,,,,,,,,,,,2.0,10000000.0,,,46.0,Weeks,Dead,73.0,,Glioblastoma,,,,,,,,,,,Stable Desease,,,,,Not significant,,,,Intradermal,,
224,,,,,,,,,,,,,,,2.0,17000000.0,,,40.0,Weeks,Dead,216.0,,Glioma,,,,,,,,,,,Stable Desease,,,,,,Female,,,Intradermal,,
225,,,,,,,,,,,,,,,4.0,42400000.0,,,53.0,Weeks,Dead,100.0,,Glioblastoma,,,,,,,,,,,Partial Response,,,,,,Female,,,Intradermal,,
226,,,,,,,,,,,,,,,1.0,12600000.0,,,47.0,Weeks,Dead,188.0,,Glioma,,,,,,,,,,,Stable Desease,,,,,,Female,,,Intradermal,,
227,,,,,,,,,,,,,,,2.0,64000000.0,,,60.0,Weeks,Dead,63.0,,Glioblastoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,Intradermal,,
228,,,,,,,,,,,,,,,10.0,137200000.0,,,65.0,Weeks,Live,308.0,,Glioblastoma,,,,,,,,,,,Partial Response,,,,,Not significant,Female,,,Intradermal,,
229,,,,,,,,,,,,,,,3.0,46000000.0,,,69.0,Weeks,Dead,52.0,,Glioblastoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,Intradermal,,
230,,,,,,,,,,,,,,,6.0,37500000.0,,,20.0,Weeks,Dead,60.0,,Glioblastoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,Intradermal,,
231,,,,,,,,,,,,,,,4.0,28200000.0,,,34.0,Weeks,Dead,98.0,,Pancreatic cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,Intradermal,,
232,,,,,,,,,,,,,,,3.0,20600000.0,,,27.0,Weeks,Dead,564.0,,Glioblastoma,,,,,,,,,,,Progressive Disease,,,,,,Female,,,Intradermal,,
233,Control antigen,-,5.0,7.0,,,,,,,,,,,,,,,62.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,Expression vector
234,Control antigen,-,13.0,16.0,,,,,,,,,,,,,,,75.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,Expression vector
235,Control antigen,-,5.0,4.0,,,,,,,,,,,,,,,58.0,,,,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,Expression vector
236,Control antigen,-,12.0,16.0,,,,,,,,,,,,,,,75.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,Lysate
237,Control antigen,-,34.0,28.0,,,,,,,,,,,,,,,78.0,,,,,,,,,,,,,,,Radiotherapy,Progressive Disease,,,,,,Male,,,,,Lysate
238,Control antigen,-,8.0,8.0,,,,,,,,,,,,,,,46.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,Expression vector
239,Control antigen,-,17.0,48.0,,,,,,,,,,,,,,,60.0,,,,,,,,,,,,,,,Hormonal therapy,Progressive Disease,,,,,,Male,,,,,Lysate
240,Control antigen,-,9.0,9.0,,,,,,,,,,,,,,,48.0,,,,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,Expression vector
241,Control antigen,-,16.0,12.0,,,,,,,,,,,,,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,Expression vector
242,Control antigen,-,6.0,20.0,,,,,,,,,,,,,,,62.0,,,,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,Expression vector
243,Control antigen,-,14.0,6.0,,,,,,,,,,,,,,,42.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,Expression vector
244,Control antigen,-,6.0,7.0,,,,,,,,,,,,,,,62.0,,,,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,Lysate
245,,,,,,,,,,,,,,30000000.0,,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,-,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
246,,,,,,,,,,,,,,1000000.0,4.0,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,-,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
247,,,,,,,,,,,,,,30000000.0,,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,-,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
248,,,,,,,,,,,,,,1000000.0,4.0,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,-,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
249,,,,,,,,,,,,,,30000000.0,,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,-,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
250,,,,,,,,,,,,,,30000000.0,,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,-,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
251,,,,,,,,,,,,,,30000000.0,,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,-,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
252,,,,,,,,,,,,,,30000000.0,,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,-,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
253,,,,,,,,,,,,,,30000000.0,,,69.0,32.0,47.0,,,,HLA-A2,,,,,,,,,,,,,-,,,HER-2/Neu,Not significant,,,,Intravenously,Metastatic,Peptide
254,Tumor antigen,Yes,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
255,Control antigen,Yes,,,,,,,,Control antigen,-,,,10000000.0,4.0,,70.0,35.0,57.0,,,,,,,,,,,,,,,,Stable Desease,Increase,,,CEA,Not significant,Male,,,Intravenously,Metastatic,RNA
256,Tumor antigen,Yes,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
257,Tumor antigen,Yes,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Female,,,Intravenously,,
258,Control antigen,Yes,,,,,,,,Control antigen,-,,,10000000.0,4.0,,70.0,35.0,57.0,,,,,,,,,,,,,,,,Progressive Disease,Increase,,,CEA,Not significant,Male,,,Intravenously,Metastatic,RNA
259,,,,,,,,,,Control antigen,-,,,10000000.0,4.0,,70.0,35.0,57.0,,,,,Colon cancer,,,,,,,,,,,Progressive Disease,Increase,,,CEA,Not significant,Male,,,Intravenously,Metastatic,RNA
260,Tumor antigen,Yes,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,,,,,,,,,,,,,,,,,Not significant,,,,Intravenously,,
261,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
262,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
263,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,,,,Intravenously,,
264,Control antigen,Yes,,,,,,,,Control antigen,-,,,10000000.0,4.0,,70.0,35.0,57.0,Days,Dead,477.0,,,,,,,,,,,,,Progressive Disease,Increase,,,CEA,Not significant,Male,,,Intravenously,Metastatic,RNA
265,Tumor antigen,Yes,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
266,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
267,,,,,,,,,,Control antigen,-,,,10000000.0,4.0,,70.0,35.0,57.0,,,,,Colon cancer,,,,,,,,,,,,Increase,,,CEA,Not significant,,,,Intravenously,Metastatic,RNA
268,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,,,,Intravenously,,
269,Tumor antigen,Yes,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
270,Control antigen,Yes,,,,,,,,Control antigen,-,,,10000000.0,4.0,,70.0,35.0,57.0,Days,Dead,477.0,,,,,,,,,,,,,Progressive Disease,Increase,,,CEA,Not significant,Male,,,Intravenously,Metastatic,RNA
271,Control antigen,Yes,,,,,,,,Control antigen,-,,,10000000.0,4.0,,70.0,35.0,57.0,Days,Dead,477.0,,Colon cancer,,,,,,,,,,,,Increase,,,CEA,Not significant,,,,Intravenously,Metastatic,RNA
272,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,,,,Intravenously,,
273,Control antigen,Yes,,,,,,,,Control antigen,-,,,10000000.0,4.0,,70.0,35.0,57.0,,,,,,,,,,,,,,,,,-,,,CA-125,Not significant,Male,,,Intravenously,Metastatic,RNA
274,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Female,,,Intravenously,,
275,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,,,,Intravenously,,
276,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
277,Control antigen,Yes,,,,,,,,Control antigen,-,,,10000000.0,4.0,,70.0,35.0,57.0,Days,Dead,477.0,,Colon cancer,,,,,,,,,,,,Increase,,,CEA,Not significant,Male,,,Intravenously,Metastatic,RNA
278,Control antigen,Yes,,,,,,,,Control antigen,-,,,10000000.0,4.0,,70.0,35.0,57.0,Days,Dead,477.0,,,,,,,,,,,,,,-,,,CA-125,Not significant,,,Immunotherapy,Intravenously,Metastatic,RNA
279,Control antigen,Yes,,,,,,,,Control antigen,-,,,10000000.0,4.0,,70.0,35.0,57.0,Days,Dead,477.0,,Colon cancer,,,,,,,,,,,,Increase,,,CEA,Not significant,Female,,Immunotherapy,Intravenously,Metastatic,RNA
280,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
281,Control antigen,Yes,,,,,,,,Tumor antigen,Yes,,,10000000.0,4.0,,70.0,35.0,57.0,Days,Dead,477.0,,Colon cancer,,,,,,,,,,,Progressive Disease,Increase,,,CEA,Not significant,Male,,Immunotherapy,Intravenously,Metastatic,RNA
282,,,,,,,,,,,,,,30000000.0,4.0,,79.0,34.0,57.0,,,,,Colon cancer,,,,,,,,,,,,,,,,Not significant,Male,,,Intravenously,,
283,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
284,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,Peptide
285,,,,,,,,,-,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,Peptide
286,,,,,,,,,-,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,Peptide
287,,,,,Tumor antigen,-,,,-,Tumor antigen,Yes,23600000.0,6.5,13400000.0,6.0,,74.0,32.0,57.0,Months,Live,6.2,HLA-A2,Melanoma,,1.0,1.0,,,,,,Monocytes,,Partial Response,,,,,,-,,Immunotherapy,Subcutaneously,IV,Peptide
288,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
289,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
290,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
291,,,,,,,,,-,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
292,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
293,,,,,,,,,-,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
294,,,,,,,,,-,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
295,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
296,,,,,Tumor antigen,-,,,-,,,23600000.0,6.5,13400000.0,6.0,,74.0,32.0,57.0,Months,Live,6.2,HLA-A2,Melanoma,,1.0,1.0,,,,,,Monocytes,,Stable Desease,,,,,,-,,Immunotherapy,Subcutaneously,IV,Peptide
297,,,,,Tumor antigen,-,,,,,,23600000.0,6.5,13400000.0,6.0,,74.0,32.0,57.0,Months,Live,6.2,HLA-A2,Melanoma,,1.0,1.0,,,,,,Monocytes,,Stable Desease,,,,,,Female,,Immunotherapy,Subcutaneously,IV,Peptide
298,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
299,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
300,,,,,,,,,-,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
301,,,,,Tumor antigen,-,,,-,,,23600000.0,6.5,13400000.0,6.0,,74.0,32.0,57.0,Months,Live,6.2,HLA-A2,Melanoma,,1.0,1.0,,,,,,Monocytes,,Partial Response,,,,,,-,,Immunotherapy,Subcutaneously,IV,Peptide
302,,,,,,,,,-,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
303,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
304,,,,,,,,,-,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
305,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
306,,,,,Tumor antigen,-,,,,,,23600000.0,6.5,13400000.0,6.0,,74.0,32.0,57.0,Months,Live,6.2,HLA-A2,Melanoma,,1.0,1.0,,,,,,Monocytes,,Partial Response,,,,,,-,,Immunotherapy,Subcutaneously,IV,Peptide
307,,,,,,,,,-,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
308,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
309,,,,,,,,,-,,,,,,,,,,,,,,,,,,,,,,,,,,Progressive Disease,,,,,,,,,,,
310,-,Yes,,,,,,,,,,,,,5.0,,,,69.0,Months,Dead,4.0,,Thyroid Cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
311,-,Yes,,,,,,,,,,,,,4.0,,,,49.0,Months,Dead,4.0,,Thyroid Cancer,,,,,,,,,,,,,,,,,Male,,,,,
312,-,No,,,,,,,,,,,,,4.0,,,,50.0,Months,Dead,3.0,,Pancreatic cancer,,,,,,,,,,,,,,,,,Male,,,,,
313,-,Yes,,,,,,,,,,,,,10.0,,,,42.0,Months,Dead,18.0,,Hepatocellular carcinoma,,,,,,,,,,,,,,,,,Male,,,,,
314,-,Yes,,,,,,,,,,,,,10.0,,,,57.0,Months,Dead,9.0,,Thyroid Cancer,,,,,,,,,,,,,,,,,Male,,,,,
315,-,Yes,,,,,,,,,,,,,8.0,,,,55.0,Months,Dead,6.0,,Cholangiocellular carcinoma,,,,,,,,,,,,,,,,,Male,,,,,
316,-,Yes,,,,,,,,,,,,,10.0,,,,62.0,Months,Live,22.0,,Cholangiocellular carcinoma,,,,,,,,,,,,,,,,,Female,,,,,
317,-,Yes,,,,,,,,,,,,,4.0,,,,52.0,Months,Dead,4.0,,Pancreatic cancer,,,,,,,,,,,,,,,,,Male,,,,,
318,-,Yes,,,,,,,,,,,,,10.0,,,,41.0,Months,Dead,9.0,,Renal cancer,,,,,,,,,,,,,,,,,Male,,,,,
319,-,Yes,,,,,,,,,,,,,7.0,,,,59.0,Months,Dead,7.0,,Pancreatic cancer,,,,,,,,,,,,,,,,,Male,,,,,
320,-,Yes,,,,,,,,,,,,,5.0,,,,60.0,Months,Dead,4.0,,Pancreatic cancer,,,,,,,,,,,,,,,,,Male,,,,,
321,-,Yes,,,,,,,,,,,,,10.0,,,,75.0,Months,Dead,12.0,,Pancreatic cancer,,,,,,,,,,,,,,,,,Male,,,,,
322,-,Yes,,,,,,,,,,,,,4.0,,,,51.0,Months,Dead,10.0,,Pancreatic cancer,,,,,,,,,,,,,,,,,Male,,,,,
323,-,Yes,,,,,,,,,,,,,6.0,,,,60.0,Months,Dead,6.0,,Pancreatic cancer,,,,,,,,,,,,,,,,,Female,,,,,
324,-,Yes,,,,,,,,,,,,,6.0,,,,63.0,Months,Dead,5.0,,Cholangiocellular carcinoma,,,,,,,,,,,,,,,,,Male,,,,,
325,-,Yes,,,,,,,,,,,,,10.0,,,,61.0,Months,Live,24.0,,Thyroid Cancer,,,,,,,,,,,,,,,,,Male,,,,,
326,-,No,,,,,,,,,,,,,4.0,,,,66.0,Months,Dead,4.0,,Pancreatic cancer,,,,,,,,,,,,,,,,,Male,,,,,
327,-,Yes,,,,,,,,,,,,,4.0,,,,71.0,Months,Dead,3.0,,Hepatocellular carcinoma,,,,,,,,,,,,,,,,,Male,,,,,
328,-,Yes,,,,,,,,,,,,,10.0,,,,44.0,Months,Dead,9.0,,Cholangiocellular carcinoma,,,,,,,,,,,,,,,,,Female,,,,,
329,-,Yes,,,,,,,,,,,,,10.0,,,,31.0,Months,Dead,32.0,,Thyroid Cancer,,,,,,,,,,,,,,,,,Male,,,,,
330,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
331,-,No,,,,,,,,,,,,,4.0,5.2,,,64.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Radiotherapy,Stable Desease,-,3797.0,6446.0,AFP,,Male,,,,,
332,-,Yes,,,,,,,,,,,,,12.0,18100000.0,,,48.0,,,,,Cholangiocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
333,-,No,,,,,,,,,,,,,5.0,7900000.0,,,70.0,,,,,Hepatocellular carcinoma,,,,,,,,,,,Stable Desease,-,14.8,113.3,PSA,,Male,,,,,
334,-,No,,,,,,,,,,,,,4.0,5700000.0,,,65.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Progressive Disease,-,5576.0,10154.0,AFP,,Male,,,,,
335,-,Yes,,,,,,,,,,,,,8.0,6300000.0,,,54.0,,,,,Hepatocellular carcinoma,,,,,,,,,,,Stable Desease,-,10.0,125.8,PSA,,Male,,,,,
336,-,Yes,,,,,,,,,,,,,4.0,7800000.0,,,65.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Chemotherapy,Progressive Disease,-,5.3,7.1,AFP,,Male,,,,,
337,-,Yes,,,,,,,,,,,,,12.0,21400000.0,,,63.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Partial Response,-,50.7,78.2,AFP,,Male,,,,,
338,-,Yes,,,,,,,,,,,,,8.0,21300000.0,,,83.0,,,,,Cholangiocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,-,116.3,121.7,CA19-9,,Female,,,,,
339,-,Yes,,,,,,,,,,,,,4.0,29400000.0,,,75.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Radiotherapy,Stable Desease,-,128.0,94.0,AFP,,Female,,,,,
340,-,Yes,,,,,,,,,,,,,8.0,30300000.0,,,63.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
341,-,No,,,,,,,,,,,,,14.0,900000.0,,,53.0,Months,-,19.0,,,,,,,,,,,,Surgery,Partial Response,,,,,,Female,,,,,
342,,,,,,,,,,,,,,,9.0,900000.0,,,60.0,Months,-,8.0,,,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
343,-,-,,1.0,,,,,,,,,,,3.0,900000.0,,,50.0,-,-,1.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
344,-,No,,,,,,,,,,,,,10.0,900000.0,,,37.0,Months,-,10.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
345,-,-,,,,,,,,,,,,,36.0,900000.0,,,39.0,Months,-,55.0,,,,,,,,,,,,Surgery,Complete response,,,,,,Male,,,,,
346,-,-,,1.0,,,,,,,,,,,6.0,5000000.0,,,47.0,Months,-,3.5,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
347,,,,,,,,,,,,,,,1.0,,,,49.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
348,,,,,,,,,,,,,,,3.0,5000000.0,,,51.0,Months,-,3.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
349,,,,,,,,,,,,,,,1.0,5000000.0,,,67.0,Months,-,1.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
350,-,-,,7.5,,,,,,,,,,,5.0,5000000.0,,,64.0,Months,-,5.5,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
351,-,-,,5.8,,,,,,,,,,,19.0,5000000.0,,,21.0,Months,-,21.0,,,,,,,,,,,,,Partial Response,,,,,,Male,,,,,
352,,,,,,,,,,,,,,,1.0,,,,49.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
353,-,-,,4.0,,,,,,,,,,,6.0,900000.0,,,66.0,Months,-,5.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
354,-,-,,41.0,,,,,,,,,,,30.0,5000000.0,,,24.0,Months,-,44.0,,,,,,,,,,,,Surgery,Complete response,,,,,,Female,,,,,
355,-,-,,7.0,,,,,,,,,,,28.0,5000000.0,,,49.0,Months,-,38.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
356,-,-,,3.0,,,,,,,,,,,3.0,900000.0,,,27.0,Months,-,10.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
357,-,No,,,,,,,,,,,,,6.0,900000.0,,,31.0,Months,-,6.5,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
358,,,,,-,-,8.0,81.0,,-,Yes,,,,3.0,10000000.0,,,55.0,Months,Live,29.0,,,,,,1.0,,,,,,,,,,,,,Male,,Surgery,,,
359,,,,,-,-,12.0,25.0,,,,,,10000000.0,3.0,,,,40.0,Months,Dead,11.1,,,,,,1.0,,,,,,,,,,,,,Male,,Immunotherapy,Intravenously,,
360,,,,,-,-,2.0,32.0,,,,,,10000000.0,3.0,,,,50.0,Months,Live,44.0,,,,,,1.0,,,,,,,,,,,,,Male,,Immunotherapy,,,
361,,,,,-,-,13.0,12.0,,,,,,,3.0,30000000.0,,,65.0,Months,Live,28.7,,,,,,1.0,,,,,,,,,,,,,Male,,Immunotherapy,,,
362,,,,,,,,,,,,,,10000000.0,3.0,,,,73.0,Months,Dead,13.0,,,,,,1.0,,,,,,,,,,,,,Male,,Radiotherapy,,,
363,,,,,-,-,11.0,89.0,,,,,,30000000.0,3.0,,,,41.0,Months,Live,26.5,,,,,,1.0,,,,,,,,,,,,,Male,,,,,
364,,,,,,,,,,,,,,10000000.0,3.0,,,,59.0,Months,Dead,5.5,,,,,,1.0,,,,,,,,,,,,,Male,,,,,
365,,,,,-,-,13.0,86.0,,,,,,10000000.0,3.0,,,,74.0,Months,Live,17.9,,,,,,1.0,,,,,,,,,,,,,Female,,Immunotherapy,,,
366,,,,,,,,,,,,,,10000000.0,3.0,,,,83.0,Months,Live,5.0,,,,,,1.0,,,,,,,,,,,,,Male,,Immunotherapy,,,
367,,,,,,,,,,,,,,10000000.0,3.0,,,,50.0,Months,Live,12.4,,,,,,1.0,,,,,,,,,,,,,Male,,Immunotherapy,,,
368,,,,,Tumor antigen,-,,,,Tumor antigen,-,,,100000.0,3.0,,79.0,39.0,60.0,Months,-,18.0,HLA-A*0201,Melanoma,,,,,,70.0,,,Monocytes,Immunotherapy,,,,,,,Male,,,Intravenously,,Peptide
369,,,,,Tumor antigen,-,,,,Tumor antigen,-,,,100000.0,3.0,,79.0,39.0,60.0,Months,-,18.0,HLA-A*0201,Melanoma,,,,,,70.0,,,Monocytes,Chemotherapy,,,,,,,Male,,,Intravenously,III,Peptide
370,,,,,Tumor antigen,-,,,,Tumor antigen,-,,,100000.0,3.0,,79.0,39.0,60.0,Months,-,18.0,HLA-A*0201,Melanoma,,,,,,70.0,,,Monocytes,Immunotherapy,,,,,,,,,,Intravenously,,Peptide
371,,,,,Tumor antigen,-,,,,Tumor antigen,-,,,100000.0,3.0,,79.0,39.0,60.0,Months,-,18.0,HLA-A*0201,Melanoma,,,,,,70.0,,,Monocytes,Immunotherapy,,,,,,,Male,,,Intravenously,III,Peptide
372,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,III,
373,,,,,Tumor antigen,-,,,,Tumor antigen,-,,,100000.0,3.0,,79.0,39.0,60.0,Months,-,18.0,HLA-A*0201,Melanoma,,,,,,70.0,,,Monocytes,-,,,,,,,Male,,,Intravenously,III,Peptide
374,,,,,Tumor antigen,-,,,,Tumor antigen,-,,,100000.0,3.0,,79.0,39.0,60.0,Months,-,18.0,HLA-A*0201,Melanoma,,,,,,70.0,,,Monocytes,-,,,,,,,Male,,,Intravenously,IV,Peptide
375,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,IV,
376,,,,,,,,,,,,,,,,,,,,Months,-,24.0,,,,,,,,,,,,Surgery,,,,,,,,,,,III,
377,,,,,,,,,,,,,,,,,,,,Months,-,24.0,,,,,,,,,,,,Surgery,,,,,,,,,,,III,
378,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,IV,
379,,,,,,,,,,,,,,,,,,,,Months,-,24.0,,,,,,,,,,,,Surgery,,,,,,,,,,,III,
380,,,,,Tumor antigen,-,,,,Tumor antigen,-,,,100000.0,3.0,,79.0,39.0,60.0,Months,-,18.0,HLA-A*0201,Melanoma,,,,,,70.0,,,Monocytes,-,,,,,,,,,,Intravenously,IV,Peptide
381,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,IV,
382,,,,,,,,,,,,,,,,,,,,Months,-,24.0,,,,,,,,,,,,Surgery,,,,,,,,,,,III,
383,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,IV,
384,,,,,,,,,,,,,,,,,,,,Months,-,24.0,,,,,,,,,,,,Surgery,,,,,,,,,,,III,
385,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Surgery,,,,,,,,,,,IV,
386,Tumor antigen,Yes,,,,,,,,,,,,,,,,,47.0,,,,,,,,,,,,,,,Immunotherapy,Partial Response,,,,,,Female,,,,II,
387,Tumor antigen,Yes,,,,,,,,,,,,,,,,,52.0,,,,,,,,,,,,,,,Chemotherapy,Partial Response,,,,,,Female,,,,I,
388,Tumor antigen,Yes,,,,,,,,,,,,,,,,,64.0,,,,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,I,
389,Tumor antigen,Yes,,,,,,,,,,,,,,,,,62.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,-,,,,II,
390,Tumor antigen,Yes,,,,,,,,,,,,,,,,,62.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,Male,,,,I,
391,-,-,,,,,,,,,,,,,,,,,65.0,,,,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,IV,
392,,,,,,,,,,,,,,,,,,,74.0,,,,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,II,
393,Tumor antigen,Yes,,,,,,,,,,,,,,,,,57.0,,,,,,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,I,
394,Tumor antigen,Yes,,,,,,,,,,,,,,,,,47.0,,,,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,II,
395,Tumor antigen,Yes,,,,,,,,,,,,,,,,,69.0,,,,,,,,,,,,,,,Chemotherapy,Partial Response,,,,,,Female,,,,III,
396,,,,,,,,,,,,,,,10.0,,,,77.0,Months,Live,10.0,,Pancreatic cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
397,,,,,,,,,,,,,,,4.0,,,,55.0,Months,-,4.0,,Cholangiocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
398,,,,,,,,,,,,,,,9.0,,,,73.0,Months,-,7.0,,Hepatocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
399,,,,,,,,,,,,,,,10.0,,,,57.0,Months,-,14.0,,Myeloma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
400,,,,,,,,,,,,,,,10.0,,,,26.0,Months,-,14.0,,Thyroid Cancer,,,,,,,,,,,Partial Response,,,,,,Female,,,,,
401,,,,,,,,,,,,,,,10.0,,,,77.0,Months,Live,10.0,,Pancreatic cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
402,,,,,,,,,,,,,,,4.0,,,,55.0,Months,-,4.0,,Cholangiocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
403,,,,,,,,,,,,,,,9.0,,,,73.0,Months,-,7.0,,Hepatocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
404,,,,,,,,,,,,,,,10.0,,,,57.0,Months,-,14.0,,Myeloma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
405,,,,,,,,,,,,,,,10.0,,,,26.0,Months,-,14.0,,Thyroid Cancer,,,,,,,,,,,Partial Response,,,,,,Female,,,,,
406,,,,,,,,,,,,,,,10.0,,,,77.0,Months,Live,10.0,,Pancreatic cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
407,,,,,,,,,,,,,,,4.0,,,,55.0,Months,-,4.0,,Cholangiocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
408,,,,,,,,,,,,,,,9.0,,,,73.0,Months,-,7.0,,Hepatocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
409,,,,,,,,,,,,,,,10.0,,,,57.0,Months,-,14.0,,Myeloma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
410,,,,,,,,,,,,,,,10.0,,,,26.0,Months,-,14.0,,Thyroid Cancer,,,,,,,,,,,Partial Response,,,,,,Female,,,,,
411,,,,,,,,,,,,,,,10.0,,,,77.0,Months,Live,10.0,,Pancreatic cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
412,,,,,,,,,,,,,,,4.0,,,,55.0,Months,-,4.0,,Cholangiocellular carcinoma,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
413,Tumor antigen,No,,,-,No,,,,,,,,0.05,8.0,,,,50.0,Months,-,3.0,,,,,,1.0,,,,,,,Partial Response,,,,,,Male,,,,,
414,Tumor antigen,No,,,,,,,,,,,,0.02,5.0,,,,67.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Male,,,,,
415,Tumor antigen,No,,,-,No,,,,,,,,0.02,3.0,,,,66.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Male,,,,,
416,Tumor antigen,No,,,-,No,,,,,,,,0.05,8.0,,,,43.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Male,,,,,
417,Tumor antigen,No,,,-,No,,,,,,,,0.02,8.0,,,,41.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,Not significant,Female,,,,,
418,Tumor antigen,No,,,-,No,,,,,,,,0.02,3.0,,,,37.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Female,,,,,
419,Tumor antigen,No,,,-,No,,,,,,,,0.05,5.0,,,,35.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Female,,,,,
420,Tumor antigen,No,,,-,No,,,,,,,,0.07,4.0,,,,57.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,-,,,,,
421,Tumor antigen,No,,,-,No,,,,,,,,0.07,8.0,,,,40.0,Months,-,40.0,,,,,,1.0,,,,,,,Complete response,,,,,Not significant,Male,,,,,
422,Tumor antigen,No,,,-,No,,,,,,,,0.09,8.0,,,,62.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Male,,,,,
423,Tumor antigen,No,,,-,No,,,,,,,,0.09,8.0,,,,75.0,Months,-,8.0,,,,,,1.0,,,,,,,Partial Response,,,,,,Female,,,,,
424,Tumor antigen,No,,,-,No,,,,,,,,0.11,6.0,,,,52.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,Not significant,Female,,,,,
425,Tumor antigen,No,,,-,No,,,,,,,,0.11,7.0,,,,48.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,Not significant,Female,,,,,
426,Tumor antigen,No,,,-,Not done,,,,,,,,0.07,8.0,,,,45.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Female,,,,,
427,Tumor antigen,No,,,-,No,,,,,,,,0.07,5.0,,,,72.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Male,,,,,
428,Tumor antigen,No,,,-,No,,,,,,,,0.07,8.0,,,,44.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,Not significant,Male,,,,,
429,Tumor antigen,No,,,-,No,,,,,,,,0.07,8.0,,,,63.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,Not significant,Male,,,,,
430,Tumor antigen,No,,,-,No,,,,,,,,0.07,5.0,,,,71.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Male,,,,,
431,-,No,,,-,No,,,,,,,,0.07,5.0,,,,31.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Female,,,,,
432,Tumor antigen,No,,,-,No,,,,,,,,0.07,5.0,,,,33.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Male,,,,,
433,Tumor antigen,No,,,-,No,,,,,,,,0.07,8.0,,,,60.0,Months,-,2.0,,,,,,1.0,,,,,,,Stable Desease,,,,,Not significant,Male,,,,,
434,Tumor antigen,No,,,-,Yes,,,,,,,,0.07,8.0,,,,39.0,,,,,,,,,1.0,,,,,,,Progressive Disease,,,,,,Female,,,,,
435,,,,,,,,,,-,No,,,,1.0,,,,60.0,,,,,Prostate cancer,,,,,,,,,,Hormonal therapy,Not evaluable,,,,,,,,,,,
436,,,,,,,,,,-,No,,,,6.0,,,,58.0,,,,,Prostate cancer,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,,,,,,
437,,,,,,,,,,-,Yes,,,,6.0,,,,72.0,,,,,Prostate cancer,,,,,,,,,,Hormonal therapy,Stable Desease,,,,,,,,,,,
438,,,,,,,,,,-,Yes,,,,6.0,,,,52.0,,,,,Prostate cancer,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,,,,,,
439,,,,,,,,,,-,No,,,,6.0,,,,57.0,,,,,Prostate cancer,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,,,,,,
440,,,,,,,,,,-,Yes,,,,6.0,,,,40.0,,,,,Breast cancer,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
441,,,,,,,,,,-,Yes,,,,3.0,,,,52.0,,,,,Breast cancer,,,,,,,,,,Chemotherapy,Partial Response,,,,,,,,,,,
442,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
443,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
444,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
445,Control antigen,-,,,Tumor antigen,-,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,-,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,,Decrease,,,PSA,Not significant,,,,Intravenously,,Protein
446,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
447,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
448,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
449,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
450,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
451,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
452,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
453,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
454,Control antigen,-,,,Tumor antigen,-,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,-,Live,,,Prostate cancer,,,,,,,,,Monocytes,Surgery,,,,,,Not significant,,,,Intravenously,,Protein
455,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
456,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
457,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
458,Control antigen,-,,,Tumor antigen,-,,,,,,100000000.0,25000000.0,,9.0,131000000.0,,,66.0,-,Live,,HLA-A2,Prostate cancer,,,,,,,,,Monocytes,Surgery,,,,,,Not significant,,,,Intravenously,,Protein
459,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
460,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
461,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
462,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
463,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
464,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
465,,,,,Tumor antigen,No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
466,,,,,,,,,,-,-,,,5000000.0,10.0,,,,46.0,Months,Live,24.0,HLA-A2,Breast cancer,,,,,,,,,,Chemotherapy,Stable Desease,,,,,Not significant,,,Immunotherapy,Subcutaneously,Metastatic,Peptide
467,,,,,,,,,,,,,,,8.0,,,,65.0,Months,Live,7.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
468,,,,,,,,,,,,,,,8.0,,,,49.0,Months,Live,17.0,,,,,,,,,,,,Radiotherapy,Partial Response,,,,,,,,,,,
469,,,,,,,,,,,,,,,7.0,,,,51.0,Months,Live,41.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
470,,,,,Tumor antigen,Yes,,,,-,-,,,5000000.0,10.0,,,,41.0,Months,Live,15.0,HLA-A2,Breast cancer,,,,,,,,,,Radiotherapy,Progressive Disease,,,,,Not significant,,,Immunotherapy,Subcutaneously,Metastatic,Peptide
471,,,,,Tumor antigen,Yes,,,,-,-,,,5000000.0,10.0,,,,62.0,Months,Live,14.0,HLA-A2,Breast cancer,,,,,,,,,,Chemotherapy,Stable Desease,,,,,Not significant,,,Immunotherapy,Subcutaneously,Metastatic,Peptide
472,,,,,,,,,,,,,,,,100000000.0,,,,Weeks,Live,8.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
473,,,,,,,,,,,,,,,,100000000.0,,,,Weeks,Live,8.0,,,,,,,,,,,,Chemotherapy,Partial Response,,,,,,,,,,,
474,,,,,,,,,,,,,,,,100000000.0,,,,Weeks,Live,4.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
475,,,,,,,,,,,,,,,,100000000.0,,,,Weeks,Live,5.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
476,,,,,,,,,,,,,,,,100000000.0,,,,Weeks,Live,4.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
477,,,,,,,,,,,,,,,,200000000.0,,,,Weeks,Live,14.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
478,,,,,,,,,,,,,,,,2000000000.0,,,,Weeks,Live,75.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
479,,,,,,,,,,,,,,,,2100000000.0,,,,Weeks,Live,18.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
480,,,,,,,,,,,,,,,,2000000000.0,,,,Weeks,Live,23.0,,,,,,,,,,,,Chemotherapy,Partial Response,,,,,,,,,,,
481,,,,,,,,,,,,,,,,2000000000.0,,,,Weeks,Live,9.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
482,,,,,,,,,,,,,,,,3000000000.0,,,,Weeks,Live,94.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
483,,,,,,,,,,,,,,,,3000000000.0,,,,Weeks,Dead,4.0,,,,,,,,,,,,Chemotherapy,Death,,,,,,,,,,,
484,,,,,,,,,,,,,,,,2000000000.0,,,,Weeks,Live,8.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
485,,,,,,,,,,,,,,,,2000000000.0,,,,Weeks,Live,77.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
486,,,,,,,,,,,,,,,,3000000000.0,,,,Weeks,Live,12.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
487,,,,,,,,,,,,,,,,3000000000.0,,,,Weeks,-,7.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
488,,,,,,,,,,,,,,,,2000000000.0,,,,Weeks,Live,20.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
489,,,,,,,,,,,,,,,,100000000.0,,,,Weeks,Live,8.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
490,,,,,,,,,,,,,,,,100000000.0,,,,Weeks,Live,8.0,,,,,,,,,,,,Chemotherapy,Partial Response,,,,,,,,,,,
491,-,Yes,,,,,,,,Tumor antigen,Yes,,,,,,,,70.0,Months,Live,21.0,,,,,,,,,,,,Hormonal therapy,Partial Response,Decrease,,,PSA,,,,,,Metastatic,
492,,,,,,,,,,,,,,,,,,,82.0,Months,Dead,8.0,,,,,,,,,,,,Radiotherapy,Partial Response,Decrease,,,PSA,,,,,,Metastatic,
493,,,,,,,,,,,,,,,,,,,64.0,Months,Dead,1.0,,,,,,,,,,,,Hormonal therapy,Progressive Disease,Decrease,,,PSA,,,,,,Metastatic,
494,,,,,,,,,,,,,,,,,,,45.0,Months,Live,21.0,,,,,,,,,,,,Hormonal therapy,Progressive Disease,Decrease,,,PSA,,,,,,Metastatic,
495,,,,,,,,,,,,,,,,,,,65.0,Months,Live,24.0,,,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,PSA,,,,,,Metastatic,
496,,,,,,,,,,,,,,,,,,,51.0,Months,Live,21.0,,,,,,,,,,,,Hormonal therapy,Progressive Disease,Decrease,,,PSA,,,,,,Metastatic,
497,,,,,,,,,,,,,,,,,,,50.0,Months,Dead,11.0,,,,,,,,,,,,Surgery,Progressive Disease,Increase,,,PSA,,,,,,Metastatic,
498,,,,,,,,,,,,,,,,,,,72.0,Months,Dead,16.0,,,,,,,,,,,,Surgery,Stable Desease,Decrease,,,PSA,,,,,,Metastatic,
499,,,,,,,,,,,,,,,,,,,72.0,Months,Live,18.0,,,,,,,,,,,,Hormonal therapy,Stable Desease,Decrease,,,PSA,,,,,,Metastatic,
500,,,,,,,,,,,,,,,,,,,64.0,Months,Live,18.0,,,,,,,,,,,,Hormonal therapy,Stable Desease,Decrease,,,PSA,,,,,,Metastatic,
501,,,,,,,,,,,,,,,,,,,59.0,Months,Live,17.0,,,,,,,,,,,,Surgery,Stable Desease,Decrease,,,PSA,,,,,,Metastatic,
502,-,Yes,,,,,,,,Tumor antigen,Yes,,,,,,,,70.0,Months,Live,21.0,,,,,,,,,,,,Hormonal therapy,Partial Response,Decrease,,,PSA,,,,,,Metastatic,
503,-,Yes,,,,,,,,,,,,,7.0,5000000.0,,,,Months,Live,31.0,,Thyroid Cancer,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,,,,,IV,
504,-,Yes,,,,,,,,,,,,,3.0,1000000.0,,,,Months,Dead,73.0,,Cutaneous T-cell lymphoma,,,,,,,,,,Chemotherapy,,,,,,,,,,,IV,
505,-,Yes,,,,,,,,,,,,,8.0,5000000.0,,,,Months,Live,38.0,,Cutaneous T-cell lymphoma,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,,
506,-,Yes,,,,,,,,,,,,,7.0,5000000.0,,,,Months,Dead,26.0,,Pancreatic cancer,,,,,,,,,,Chemotherapy,,,,,,,,,,,IV,
507,-,No,,,,,,,,,,,,,8.0,5000000.0,,,,Months,Dead,46.0,,Renal cancer,,,,,,,,,,Surgery,,,,,,,,,,,IV,
508,-,No,,,,,,,,,,,,,9.0,5000000.0,,,,Months,Live,23.0,,Cutaneous T-cell lymphoma,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,IV,
509,-,No,,,,,,,,,,,,,5.0,5000000.0,,,,Months,Dead,22.0,,Pancreatic cancer,,,,,,,,,,Chemotherapy,,,,,,,,,,,IV,
510,-,No,,,,,,,,,,,,,4.0,5000000.0,,,,Months,Dead,18.0,,Glioblastoma,,,,,,,,,,Surgery,,,,,,,,,,,IV,
511,-,No,,,,,,,,,,,,,8.0,5000000.0,,,,Months,Dead,14.0,,Glioblastoma,,,,,,,,,,Surgery,,,,,,,,,,,IV,
512,-,No,,,,,,,,,,,,,5.0,5000000.0,,,,Months,Dead,7.0,,Pancreatic cancer,,,,,,,,,,Surgery,,,,,,,,,,,IV,
513,-,No,,,,,,,,,,,,,5.0,5.0,,,,Months,Dead,30.0,,Glioblastoma,,,,,,,,,,Surgery,,,,,,,,,,,IV,
514,-,No,,,,,,,,,,,,,5.0,5000000.0,,,,Months,Dead,33.0,,Pancreatic cancer,,,,,,,,,,Surgery,,,,,,,,,,,IV,
515,-,No,,,,,,,,,,,,,4.0,5000000.0,,,,Months,Dead,11.0,,Melanoma,,,,,,,,,,Radiotherapy,,,,,,,,,,,IV,
516,-,Yes,,,,,,,,,,,,,8.0,5000000.0,,,,Months,Dead,49.0,,Thyroid Cancer,,,,,,,,,,Surgery,,,,,,,,,,,IV,
517,-,No,,,,,,,,,,,,,5.0,5000000.0,,,,Months,Live,10.0,,Renal cancer,,,,,,,,,,Surgery,,,,,,,,,,,IV,
518,-,No,,,,,,,,,,,,,3.0,5000000.0,,,,Months,Dead,21.0,,Pancreatic cancer,,,,,,,,,,Surgery,,,,,,,,,,,IV,
519,-,Yes,,,,,,,,,,,,,4.0,5000000.0,,,,Months,Live,24.0,,Cutaneous T-cell lymphoma,,,,,,,,,,Chemotherapy,,,,,,,,,,,IV,
520,-,Yes,,,,,,,,,,,,,12.0,5000000.0,,,,Months,Live,279.0,,Thyroid Cancer,,,,,,,,,,Surgery,,,,,,,,,,,IV,
521,,,,,-,-,,,,,,,,,5.0,,,,37.0,Months,-,30.0,,Cervical cancer,,,,,,,,,,Surgery,Complete response,,,,,,,Caucasoid,,,I,
522,Tumor antigen,Yes,,,Tumor antigen,Yes,,2.15,,Tumor antigen,Yes,,,,5.0,15000000.0,72.0,23.0,31.0,Months,-,31.0,,Cervical cancer,,,,,,,,,Monocytes,Surgery,Complete response,Yes,,,HPV16/18 E7,Not significant,,-,,Subcutaneously,I,Protein
523,Tumor antigen,Yes,,,Tumor antigen,Yes,,2.15,,Tumor antigen,Yes,,,,5.0,15000000.0,72.0,23.0,32.0,Months,-,30.0,,Cervical cancer,,,,,,,,,Monocytes,Surgery,Complete response,Yes,,,HPV16/18 E7,Not significant,,Caucasoid,,Subcutaneously,I,Protein
524,Tumor antigen,Yes,,,Tumor antigen,Yes,,2.15,,Tumor antigen,Yes,,,,5.0,15000000.0,72.0,23.0,34.0,Months,-,26.0,,Cervical cancer,,,,,,,,,Monocytes,Surgery,Complete response,Yes,,,HPV16/18 E7,Not significant,,Caucasoid,,Subcutaneously,I,Protein
525,,,,,,,,,,,,,,,5.0,,,,43.0,Months,-,26.0,,Prostate cancer,,,,,,,,,,Surgery,Complete response,,,,,,,Caucasoid,,,I,
526,Tumor antigen,Yes,,,Tumor antigen,Yes,,2.15,,Tumor antigen,Yes,,,,5.0,15000000.0,72.0,23.0,72.0,Months,-,25.0,,Cervical cancer,,,,,,,,,Monocytes,Surgery,Complete response,Yes,,,HPV16/18 E7,Not significant,,Caucasoid,,Subcutaneously,I,Protein
527,,,,,,,,,,,,,,,5.0,,,,39.0,Months,-,25.0,,Prostate cancer,,,,,,,,,,Surgery,Complete response,,,,,,,Caucasoid,,,I,
528,Tumor antigen,Yes,,,Tumor antigen,Yes,,2.15,,Tumor antigen,Yes,,,,5.0,15000000.0,72.0,23.0,23.0,Months,-,20.0,,Cervical cancer,,,,,,,,,Monocytes,Surgery,Complete response,Yes,,,HPV16/18 E7,Not significant,,Caucasoid,,Subcutaneously,I,Protein
529,Tumor antigen,Yes,,,Tumor antigen,Yes,,2.15,,Tumor antigen,Yes,,,,5.0,15000000.0,72.0,23.0,32.0,Months,-,19.0,,Cervical cancer,,,,,,,,,Monocytes,Surgery,Complete response,Yes,,,HPV16/18 E7,Not significant,,Caucasoid,,Subcutaneously,I,Protein
530,Tumor antigen,Yes,,,Tumor antigen,Yes,,2.15,,Tumor antigen,Yes,,,,5.0,15000000.0,72.0,23.0,23.0,Months,-,17.0,,Cervical cancer,,,,,,,,,Monocytes,Surgery,Complete response,Yes,,,HPV16/18 E7,Not significant,,Caucasoid,,Subcutaneously,I,Protein
531,,,,,,,,,,Control antigen,Yes,,,,,,,,55.0,,,,HLA-A24,Solid malignancies,,1.0,1.0,,,,,,Monocytes,Surgery,,-,,,CEA,,Female,,-,,Metastatic,Peptide
532,,,,,,,,,,,,,,,,,,,56.0,,,,,Rectum cancer,,,,,,,,,,Surgery,,,,,,,Male,,,,,
533,,,,,,,,,,,,,,,,,,,52.0,,,,,Lung cancer,,,,,,,,,,Surgery,,,,,,,Female,,,,,
534,,,,,,,,,,,,,,,,,,,28.0,,,,,Colon cancer,,,,,,,,,,Surgery,,,,,,,Female,,,,,
535,,,,,,,,,,,,,,,,,,,42.0,,,,,Colon cancer,,,,,,,,,,Surgery,,,,,,,Female,,,,,
536,,,,,,,,,,,,,,,,,,,33.0,,,,,Stomach cancer,,,,,,,,,,Chemotherapy,,,,,,,Female,,,,,
537,,,,,,,,,,,,,,,,,,,60.0,,,,,Colon cancer,,,,,,,,,,Surgery,,,,,,,Female,,,,,
538,,,,,,,,,,,,,,,,,,,63.0,,,,,Colon cancer,,,,,,,,,,Surgery,,,,,,,Female,,,,,
539,,,,,,,,,,,,,,,,,,,69.0,,,,,Lung cancer,,,,,,,,,,Surgery,,,,,,,Male,,,,,
540,,,,,,,,,,,,,,,,,,,46.0,,,,,Colon cancer,,,,,,,,,,Surgery,,,,,,,Female,,,,,
541,,,,,,,,,,,,,,,,,,,53.0,,,,,Stomach cancer,,,,,,,,,,Surgery,,,,,,,Male,,,,,
542,,,,,,,,,,,,,,,,,,,65.0,,,,,Colon cancer,,,,,,,,,,Surgery,,,,,,,Female,,,,,
543,,,,,,,,,,,,,,,,,,,56.0,,,,,Lung cancer,,,,,,,,,,Surgery,,,,,,,Male,,,,,
544,,,,,Tumor antigen,Yes,,,,,,,,,10.0,,,,58.0,Months,Live,14.0,,,,,,,,,,,,Hormonal therapy,Stable Desease,,,,,,,,,,,
545,,,,,Tumor antigen,Yes,,,,,,,,,9.0,,,,47.0,Months,-,9.0,,,,,,,,,,,,,Stable Desease,,,,,,,,,,,
546,,,,,Tumor antigen,No,,,,,,,,,9.0,,,,46.0,Months,-,26.5,,,,,,,,,,,,Hormonal therapy,Stable Desease,,,,,,,,,,,
547,,,,,Tumor antigen,-,,,,,,,,,10.0,,,,64.0,Months,-,21.0,,,,,,,,,,,,Hormonal therapy,Stable Desease,,,,,,,,,,,
548,,,,,Tumor antigen,-,,,,,,,,,3010.0,,,,44.0,Months,-,12.5,,,,,,,,,,,,Hormonal therapy,Partial Response,,,,,,,,,,,
549,,,,,Tumor antigen,Yes,,,,,,,,,10.0,,,,58.0,Months,-,13.0,,,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,,,,,,
550,,,,,Tumor antigen,Yes,,,,,,,,,10.0,,,,74.0,Months,Live,5.5,,,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,,,,,,
551,,,,,Tumor antigen,-,,,,,,,,,8.0,,,,66.0,Months,-,21.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
552,,,,,Tumor antigen,-,,,,,,,,,7.0,,,,72.0,Months,-,4.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
553,,,,,Tumor antigen,-,,,,,,,,,5.0,,,,54.0,Months,-,2.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
554,,,,,Tumor antigen,-,,,,,,,,,1006.0,,,,59.0,Months,-,7.0,,,,,,,,,,,,Chemotherapy,Not applicable,,,,,,,,,,,
555,,,,,Tumor antigen,No,,,,,,,,,5.0,,,,33.0,Months,-,2.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
556,,,,,Tumor antigen,-,,,,,,,,,7.0,,,,46.0,Months,-,13.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
557,,,,,Tumor antigen,-,,,,,,,,,6.0,,,,51.0,Months,-,10.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
558,,,,,Tumor antigen,-,,,,,,,,,6.0,,,,64.0,Months,-,2.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
559,,,,,Tumor antigen,-,,,,,,,,,505.0,,,,64.0,Months,-,2.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
560,,,,,Tumor antigen,-,,,,,,,,,7.0,,,,52.0,Months,-,3.0,,,,,,,,,,,,Hormonal therapy,Progressive Disease,,,,,,,,,,,
561,,,,,Tumor antigen,-,,,,,,,,,6.0,,,,64.0,Months,-,21.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
562,,,,,Tumor antigen,-,,,,,,,,,6.0,,,,62.0,Months,-,9.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
563,,,,,Tumor antigen,-,,,,,,,,,3.0,,,,51.0,Months,-,1.0,,,,,,,,,,,,Hormonal therapy,Progressive Disease,,,,,,,,,,,
564,,,,,Tumor antigen,Not done,,,,,,,,,3.0,,,,61.0,Months,-,1.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
565,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,56.0,Months,-,8.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
566,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,36.0,Months,-,4.5,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
567,,,,,Tumor antigen,-,,,,,,,,,4.0,,,,44.0,Months,-,4.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
568,,,,,Tumor antigen,-,,,,,,,,,3.0,,,,58.0,Months,-,4.0,,,,,,,,,,,,Hormonal therapy,Progressive Disease,,,,,,,,,,,
569,,,,,Tumor antigen,-,,,,,,,,,4.0,,,,56.0,Months,-,1.5,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,,
570,,,,,,,,,,,,,,,,,,,70.0,,,,,,,,,,,,,,,Surgery,Complete response,,,,,,,,,,I,
571,,,,,,,,,,,,,,,,,,,62.0,,,,,,,,,,,,,,,Surgery,Complete response,,,,,,,,,,I,
572,,,,,,,,,,,,,,,,,,,66.0,,,,,,,,,,,,,,,Surgery,Complete response,,,,,,,,,,I,
573,,,,,,,,,,,,,,,,,,,65.0,,,,,,,,,,,,,,,Surgery,Complete response,,,,,,,,,,I,
574,,,,,,,,,,,,,,,,,,,56.0,,,,,,,,,,,,,,,Surgery,Stable Desease,,,,,,,,,,I,
575,,,,,,,,,,,,,,,,,,,60.0,,,,,,,,,,,,,,,Surgery,Complete response,,,,,,,,,,I,
576,,,,,,,,,,,,,,,,,,,67.0,,,,,,,,,,,,,,,Surgery,Complete response,,,,,,,,,,II,
577,,,,,,,,,,,,,,,,,,,59.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,III,
578,,,,,,,,,,,,,,,2.0,10000000.0,,,67.0,-,-,,,Lung cancer,,,,,,,,,Monocytes,Chemotherapy,Progressive Disease,-,,,HER-2/Neu,None,,,,Intradermal,III,Protein
579,,,,,Tumor antigen,No,,,,,,,,,2.0,10000000.0,,,51.0,-,-,,,Lung cancer,,,,,,,,,Monocytes,Chemotherapy,Progressive Disease,-,,,HER-2/Neu,None,,,,Intradermal,III,Protein
580,,,,,,,,,,,,,,,,,,,48.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
581,,,,,,,,,,,,,,,,,,,50.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
582,,,,,,,,,,,,,,,,,,,63.0,,,,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,,,,,,I,
583,,,,,,,,,,,,,,,,,,,58.0,,,,,,,,,,,,,,,Chemotherapy,Stable Desease,,,,,,,,,,III,
584,,,,,,,,,,,,,,,,,,,48.0,,,,,Ovarian cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
585,,,,,,,,,,,,,,,,,,,56.0,,,,,Bladder cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
586,,,,,,,,,,,,,,,,,,,62.0,,,,,Ovarian cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
587,,,,,,,,,,,,,,,,,,,37.0,,,,,Thyroid Cancer,,,,,,,,,,,Partial Response,,,,,,Female,,,,,
588,,,,,,,,,,,,,,,,,,,42.0,,,,,Fibrosarcoma,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
589,,,,,,,,,,,,,,,,,,,71.0,,,,,Pancreatic cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
590,,,,,,,,,,,,,,,,,,,46.0,,,,,Pancreatic cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,
591,,,,,,,,,,,,,,,,,,,53.0,,,,,Ovarian cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
592,,,,,,,,,,,,,,,,,,,68.0,,,,,Renal cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
593,,,,,,,,,,,,,,,,,,,47.0,,,,,Lung cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
594,,,,,,,,,,,,,,,,,,,37.0,,,,,Renal cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
595,,,,,,,,,,,,,,,,,,,73.0,,,,,Pancreatic cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
596,,,,,,,,,,,,,,,,,,,66.0,,,,,Pancreatic cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,
597,,,,,,,,,,,,,,,,,,,43.0,,,,,Thyroid Cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
598,,,,,,,,,,,,,,,,,,,45.0,,,,,Ovarian cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
599,-,No,,,,,,,,,,,,,16.0,,,,154.0,Days,Live,1370.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
600,-,No,,,,,,,,,,,,,5.0,,,,252.0,Days,Live,151.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,,
601,-,No,,,,,,,,,,,,,16.0,,,,372.0,Days,Live,379.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
602,-,No,,,,,,,,,,,,,9.0,,,,446.0,Days,-,1313.0,,,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
603,-,No,,,,,,,,,,,,,16.0,,,,568.0,Days,-,1174.0,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
604,-,No,,,,,,,,,,,,,16.0,,,,667.0,Days,-,1048.0,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
605,Tumor antigen,Yes,,,Tumor antigen,No,,,,,,,,,,,,,61.0,Months,Live,43.0,,,,,,,,,,,,,Stable Desease,,,,,,Female,,,,II,
606,Tumor antigen,No,,,Tumor antigen,Yes,,,,,,,,,,,,,55.0,Months,-,40.0,,,,,,,,,,,,,Partial Response,,,,,,Male,,,,I,
607,Tumor antigen,No,,,Tumor antigen,No,,,,,,,,,,,,,50.0,Months,-,29.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,III,
608,Tumor antigen,No,,,Tumor antigen,No,,,,,,,,,,,,,63.0,Months,-,43.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,III,
609,Tumor antigen,No,,,Tumor antigen,Yes,,,,,,,,,,,,,59.0,Months,-,10.0,,,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,I,
610,Tumor antigen,No,,,Tumor antigen,No,,,,,,,,,,,,,55.0,Months,-,1.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,II,
611,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,,,,,,54.0,Months,-,28.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,I,
612,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,,,,,,37.0,Months,-,1.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,III,
613,Tumor antigen,No,,,Tumor antigen,Yes,,,,,,,,,,,,,59.0,Months,-,1.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,III,
614,Tumor antigen,No,,,Tumor antigen,Yes,,,,,,,,,,,,,62.0,Months,-,24.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,I,
615,Tumor antigen,No,,,Tumor antigen,No,,,,,,,,,,,,,59.0,Months,-,13.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,I,
616,Tumor antigen,No,,,Tumor antigen,No,,,,,,,,,,,,,68.0,Months,-,10.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,I,
617,Tumor antigen,No,,,Tumor antigen,No,,,,,,,,,,,,,58.0,Months,-,1.0,,,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,I,
618,Tumor antigen,Yes,,,Tumor antigen,Yes,,,,,,,,,,,,,54.0,Months,-,9.0,,,,,,,,,,,,,Stable Desease,,,,,,Female,,,,I,
619,Tumor antigen,No,,,Tumor antigen,Yes,,,,,,,,,,,,,66.0,Months,-,9.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,III,
620,,,,,,,,,,,,,,,1.0,,,,57.0,Weeks,Dead,16.0,,,,,,1.0,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
621,,,,,,,,,,,,,,,,,,,63.0,,,,,,,,,1.0,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
622,,,,,,,,,,,,,,,,,,,77.0,,,,,,,,,1.0,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
623,,,,,,,,,,,,,,,,,,,,,,,,Stomach cancer,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,-,Not significant,,,,,,
624,,,,,,,,,,,,,,,,,,,,,,,,Solid malignancies,,,,,,,,,,Surgery,Partial Response,Decrease,,,-,Not significant,,,,,,
625,,,,,,,,,,,,,,,,,,,,,,,,Solid malignancies,,,,,,,,,,Chemotherapy,Progressive Disease,-,,,-,Not significant,,,,,,
626,,,,,,,,,,,,,,,,,,,,,,,,Solid malignancies,,,,,,,,,,Chemotherapy,Partial Response,Decrease,,,-,Not significant,,,,,,
627,,,,,,,,,,,,,,,4.0,3e+14,,,,,,,HLA-A2,Stomach cancer,,2.0,1.0,,,,,OK-432,,Surgery,Progressive Disease,-,,,-,Not significant,,,,Subcutaneously,Metastatic,Peptide
628,,,,,,,,,,,,,,,,,,,,,,,,Stomach cancer,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,-,Not significant,,,,,,
629,,,,,,,,,,,,,,,,,,,,,,,,Stomach cancer,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,-,Not significant,,,,,,
630,,,,,,,,,,,,,,,,,,,,,,,,Stomach cancer,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,-,Not significant,,,,,,
631,,,,,,,,,,,,,,,4.0,3e+14,,,,,,,HLA-A2,Stomach cancer,,2.0,1.0,,,,,OK-432,,Surgery,Progressive Disease,-,,,-,Not significant,,,,Subcutaneously,Metastatic,Peptide
632,,,,,,,,,,,,,,,,,,,,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,Decrease,,,-,Not significant,,,,,,
633,,,,,,,,,,,,,,,,,,,,,,,,Colon cancer,,,,,,,,,,Surgery,Progressive Disease,-,,,-,Not significant,,,,,,
634,,,,,,,,,,,,,,,,,,,,,,,,Colon cancer,,,,,,,,,,Surgery,Progressive Disease,-,,,-,Not significant,,,,,,
635,,,,,,,,,,,,,,,4.0,3e+14,,,,,,,HLA-A2,Stomach cancer,,2.0,1.0,,,,,OK-432,,Surgery,Progressive Disease,-,,,-,Not significant,,,,Subcutaneously,Metastatic,Peptide
636,,,,,,,,,,,,,,,,,,,,,,,,Stomach cancer,,,,,,,,,,Surgery,Progressive Disease,Decrease,,,-,Not significant,,,,,,
637,Tumor antigen,Yes,,,,,,,,,,,,,4.0,3e+14,,,,,,,HLA-A2,Stomach cancer,,2.0,1.0,,,,,OK-432,,Surgery,Progressive Disease,-,,,-,Not significant,,,,Subcutaneously,Metastatic,Peptide
638,,,,,,,,,,,,,,,,,,,,,,,,Colon cancer,,,,,,,,,,Surgery,Stable Desease,Decrease,,,-,Not significant,,,,,,
639,,,,,,,,,,,,,,,,,,,,,,,,Bladder cancer,,,,,,,,,,Surgery,Partial Response,Decrease,,,-,Not significant,,,,,,
640,,,,,,,,,,,,,,,,,,,,,,,,Colon cancer,,,,,,,,,,Surgery,Progressive Disease,-,,,-,Not significant,,,,,,
641,,,,,,,,,,,,,,,4.0,3e+14,,,,,,,HLA-A2,Stomach cancer,,2.0,1.0,,,,,OK-432,,Surgery,Progressive Disease,-,,,-,Not significant,,,,Subcutaneously,Metastatic,Peptide
642,,,,,,,,,,,,,,,,,,,,,,,,Solid malignancies,,,,,,,,,,Surgery,Progressive Disease,-,,,-,Not significant,,,,,,
643,,,,,,,,,,,,,,,,,,,,,,,,Solid malignancies,,,,,,,,,,Surgery,Progressive Disease,-,,,-,Not significant,,,,,,
644,,,,,,,,,,,,,,,,,,,,,,,,Colon cancer,,,,,,,,,,Surgery,Progressive Disease,-,,,-,Not significant,,,,,,
645,,,,,,,,,,,,,,,,,,,,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Progressive Disease,-,,,-,Not significant,,,,,,
646,,,,,,,,,,,,,,,,,,,,,,,,Solid malignancies,,,,,,,,,,Chemotherapy,Progressive Disease,Decrease,,,-,Not significant,,,,,,
647,,,,,,,,,,,,,,,,,,,,,,,,Bladder cancer,,,,,,,,,,Surgery,Progressive Disease,-,,,-,Not significant,,,,,,
648,,,,,,,,,,,,,,,,,,,,,,,,Colon cancer,,,,,,,,,,Surgery,Progressive Disease,-,,,-,Not significant,,,,,,
649,,,,,,,,,,,,,,,,,,,,,,,,Solid malignancies,,,,,,,,,,Surgery,Progressive Disease,-,,,-,Not significant,,,,,,
650,,,,,,,,,,,,,,,,,,,,,,,,Solid malignancies,,,,,,,,,,Surgery,Progressive Disease,No change,,,-,Not significant,,,,,,
651,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
652,,,,,,,,,,,,,,,4.0,5.0,,,42.0,Months,-,10.0,,,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,III,
653,,,,,,,,,,,,,,,4.0,5.0,,,57.0,Months,-,62.0,,,,,,,,,,,,,Complete response,,,,,,Female,,,,III,
654,,,,,,,,,,,,,,,4.0,5.0,,,32.0,Months,-,43.0,,,,,,,,,,,,,Complete response,,,,,,Male,,,,III,
655,,,,,,,,,,,,,,,4.0,5.0,,,17.0,Months,-,53.0,,,,,,,,,,,,,Complete response,,,,,,Female,,,,III,
656,,,,,,,,,,,,,,,4.0,10.0,,,56.0,Months,-,4.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
657,,,,,,,,,,,,,,,4.0,3.0,,,60.0,Months,-,45.0,,,,,,,,,,,,,Complete response,,,,,,Male,,,,III,
658,,,,,,,,,,,,,,,2.0,10.0,,,27.0,Months,-,1.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
659,,,,,,,,,,,,,,,4.0,10.0,,,26.0,Months,-,7.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
660,,,,,,,,,,,,,,,4.0,15.0,,,42.0,Months,-,79.0,,,,,,,,,,,,,Complete response,,,,,,Female,,,,III,
661,,,,,,,,,,,,,,,4.0,15.0,,,34.0,Months,-,11.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
662,,,,,,,,,,,,,,,4.0,15.0,,,44.0,Months,-,4.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
663,,,,,,,,,,,,,,,4.0,15.0,,,56.0,Months,-,33.0,,,,,,,,,,,,,Complete response,,,,,,Male,,,,III,
664,,,,,,,,,,,,,,,4.0,20.0,,,47.0,Months,-,34.0,,,,,,,,,,,,,Complete response,,,,,,Male,,,,II,
665,,,,,,,,,,,,,,,4.0,20.0,,,30.0,Months,-,47.0,,,,,,,,,,,,,Complete response,,,,,,Male,,,,III,
666,,,,,,,,,,,,,,,4.0,20.0,,,52.0,Months,-,10.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
667,,,,,,,,,,,,,,,4.0,20.0,,,57.0,Months,-,6.0,,,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,IV,
668,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
669,,,,,,,,,,,,,,,10.0,,,,57.0,Months,Live,29.5,,,,,,,,,,,,,Stable Desease,,,,,,Male,,Immunotherapy,,,
670,,,,,Tumor antigen,Yes,,,KLH,,,,,,13.0,,79.0,38.0,79.0,Months,-,25.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Stable Desease,,,,,Not significant,Female,,Immunotherapy,,,Lysate
671,,,,,Tumor antigen,Yes,,,KLH,,,,,,10.0,,79.0,38.0,61.0,Months,-,7.5,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
672,,,,,Tumor antigen,Yes,,,KLH,,,,,,6.0,,79.0,38.0,60.0,Months,-,5.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
673,,,,,Tumor antigen,Yes,,,KLH,,,,,,13.0,,79.0,38.0,38.0,Months,-,16.5,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
674,,,,,Tumor antigen,Yes,,,KLH,,,,,,21.0,,79.0,38.0,61.0,Months,-,20.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
675,,,,,Tumor antigen,Yes,,,KLH,,,,,,13.0,,79.0,38.0,78.0,Months,-,11.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
676,,,,,Tumor antigen,Yes,,,KLH,,,,,,23.0,,79.0,38.0,66.0,Months,-,16.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Stable Desease,,,,,Not significant,Female,,Immunotherapy,,,Lysate
677,,,,,Tumor antigen,Yes,,,KLH,,,,,,6.0,,79.0,38.0,59.0,Months,-,6.5,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Progressive Disease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
678,,,,,Tumor antigen,Yes,,,KLH,,,,,,6.0,,79.0,38.0,60.0,Months,-,3.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Progressive Disease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
679,,,,,Tumor antigen,Yes,,,KLH,,,,,,6.0,,79.0,38.0,54.0,Months,-,5.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Progressive Disease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
680,,,,,Tumor antigen,Yes,,,KLH,,,,,,6.0,,79.0,38.0,42.0,Months,-,10.5,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Progressive Disease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
681,,,,,Tumor antigen,Yes,,,KLH,,,,,,6.0,,79.0,38.0,70.0,Months,-,4.5,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Progressive Disease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
682,,,,,Tumor antigen,Yes,,,KLH,,,,,,6.0,,79.0,38.0,59.0,Months,-,13.0,HLA-A2 negative,Renal cancer,,,,,,,,IL-1β,Monocytes,,Progressive Disease,,,,,Not significant,Male,,Immunotherapy,,,Lysate
683,Tumor antigen,No,,,,,,,,Control antigen,Yes,,,,,30000000.0,,,44.0,Months,Live,41.0,,Glioblastoma,,,,,,,,,,Radiotherapy,,,,,,,Male,,,,,
684,Tumor antigen,No,,,,,,,,Control antigen,Yes,,,,,30000000.0,,,40.0,Months,-,12.3,,Glioma,,,,,,,,,,Radiotherapy,,,,,,,Female,,,,,
685,Tumor antigen,No,,,,,,,,Control antigen,Yes,,,,,30000000.0,,,50.0,Months,-,17.5,,Glioma,,,,,,,,,,Radiotherapy,,,,,,,Male,,,,,
686,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,100000000.0,,,37.0,Months,-,15.9,,Glioma,,,,,,,,,,Chemotherapy,,,,,,,Male,,,,,
687,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,100000000.0,,,37.0,Months,-,6.7,,Glioma,,,,,,,,,,Radiotherapy,,,,,,,Male,,,,,
688,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,100000000.0,,,58.0,Months,-,20.0,,Glioma,,,,,,,,,,Chemotherapy,,,,,,,Female,,,,,
689,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,100000000.0,,,55.0,Months,-,19.6,,Glioma,,,,,,,,,,Radiotherapy,,,,,,,Female,,,,,
690,Tumor antigen,Yes,,,,,,,,Control antigen,Yes,,,,,55000000.0,,,44.0,Months,-,40.8,,Glioma,,,,,,,,,,Chemotherapy,,,,,,,Male,,,,,
691,Tumor antigen,No,,,,,,,,Control antigen,Yes,,,,,23000000.0,,,34.0,Months,-,65.4,,Glioma,,,,,,,,,,Chemotherapy,,,,,,,Female,,,,,
692,Tumor antigen,No,,,,,,,,Control antigen,Yes,,,,,29000000.0,,,55.0,Months,-,25.6,,Glioma,,,,,,,,,,Radiotherapy,,,,,,,Male,,,,,
693,Tumor antigen,No,,,,,,,,Control antigen,Yes,,,,,57000000.0,,,35.0,Months,-,28.1,,Glioma,,,,,,,,,,Radiotherapy,,,,,,,Male,,,,,
694,Tumor antigen,No,,,,,,,,Control antigen,-,,,,,76000000.0,,,36.0,Months,-,46.2,,Glioma,,,,,,,,,,Radiotherapy,,,,,,,Male,,,,,
695,,,,,,,,,,,,,,,,0.23,,,37.0,,,,,Renal cancer,,,,,,,,,,,,,,,,,Female,,,,III,
696,,,,,,,,,,,,,,,,5.1,,,55.0,,,,,Renal cancer,,,,,,,,,,,,,,,,,Male,,,,III,
697,,,,,,,,,,,,,,,,1.75,,,68.0,,,,,Renal cancer,,,,,,,,,,,,,,,,,Female,,,,III,
698,,,,,,,,,,,,,,,,2.6,,,56.0,,,,,Renal cancer,,,,,,,,,,,,,,,,,Male,,,,III,
699,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
700,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
701,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
702,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
703,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
704,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
705,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
706,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
707,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
708,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
709,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
710,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
711,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
712,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
713,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
714,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
715,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
716,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
717,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
718,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
719,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
720,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
721,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
722,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
723,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
724,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
725,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
726,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
727,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
728,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
729,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
730,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
731,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,,Intravenously,Metastatic,Peptide
732,,,,,,,,,KLH,,,,,5000000.0,,,,,,,,,HLA-A2,Melanoma,,,,,,,,PGE2,Monocytes,,,,,,,,,,Immunotherapy,Intravenously,Metastatic,Peptide
733,,,,,,,,,,-,-,,,,,,,,61.0,Days,-,84.0,,,,,,1.0,,,,,,,Partial Response,,,,,,Male,,,,III,
734,,,,,,,,,,,,,,,,,,,66.0,Days,-,198.0,,,,,,2.0,,,,,,,Stable Desease,,,,,,Male,,,,III,
735,,,,,,,,,,,,,,,,,,,59.0,Days,-,112.0,,,,,,1.0,,,,,,,Stable Desease,,,,,,Male,,,,III,
736,,,,,,,,,,,,,,,,,,,63.0,Days,-,82.0,,,,,,2.0,,,,,,,Stable Desease,,,,,,Female,,,,IV,
737,,,,,,,,,,,,,,,,,,,50.0,Days,-,277.0,,-,,,,,,,,,,,Partial Response,,,,,,Female,,,,-,
738,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
739,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
740,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
741,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
742,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
743,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
744,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
745,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
746,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
747,,,,,Tumor antigen,No,,,,Tumor antigen,Yes,,,,8.0,106.7,,,62.0,,,,HLA-A*2402,Colorectal cancer,,2.0,1.0,,,,,OK-432,Monocytes,,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Subcutaneously,IV,Peptide
748,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
749,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
750,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
751,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
752,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
753,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
754,,,,,,,,,,,,,,,4.0,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,2.0,1.0,,,,,,,Surgery,Stable Desease,,,,,Not significant,Female,,,Intravenously,,Peptide
755,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
756,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
757,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
758,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
759,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
760,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
761,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
762,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
763,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
764,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
765,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
766,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
767,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
768,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,2.0,1.0,,,,,,,Surgery,Not evaluable,,,,,Not significant,Female,,,Intravenously,,Peptide
769,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
770,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
771,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
772,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
773,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
774,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
775,,,,,,,,,,,,,,,,30000000.0,,,65.0,,,,,Prostate cancer,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,,
776,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
777,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
778,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
779,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
780,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
781,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
782,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
783,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
784,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
785,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
786,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
787,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
788,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
789,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
790,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
791,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
792,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
793,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
794,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
795,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
796,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
797,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
798,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
799,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
800,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
801,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
802,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
803,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
804,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
805,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
806,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
807,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,2.0,1.0,,,,,,,Surgery,Not evaluable,,,,,Not significant,Female,,,Intravenously,,Peptide
808,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
809,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
810,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
811,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
812,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
813,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
814,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
815,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
816,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
817,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
818,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
819,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
820,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
821,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
822,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
823,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
824,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
825,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
826,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
827,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
828,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
829,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
830,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
831,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
832,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
833,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
834,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
835,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
836,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
837,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
838,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
839,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
840,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
841,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
842,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
843,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
844,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
845,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
846,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
847,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
848,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
849,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
850,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
851,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
852,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
853,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
854,,,,,,,,,,,,,,,,2000000.0,,,57.0,,,,,Renal cancer,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
855,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
856,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
857,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
858,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
859,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
860,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
861,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,2.0,1.0,,,,,,,Surgery,Not evaluable,,,,,Not significant,Female,,,Intravenously,,Peptide
862,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
863,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
864,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
865,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
866,,,,,,,,,,,,,,,4.0,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,2.0,1.0,,,,,,,Surgery,Stable Desease,Decrease,,,CEA,Not significant,Female,,,Intravenously,,Peptide
867,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
868,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
869,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
870,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
871,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
872,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
873,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
874,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
875,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
876,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
877,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
878,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
879,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
880,,,,,,,,,,,,,,,,2000000.0,,,51.0,,,,,Pancreatic cancer,,,,,,,,,,Immunotherapy,Not evaluable,,,,,,Male,,,,,
881,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
882,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
883,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
884,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
885,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
886,,,,,,,,,,,,,,,,2000000.0,,,51.0,,,,,Pancreatic cancer,,,,,,,,,,Immunotherapy,Not evaluable,,,,,,Male,,,,,
887,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
888,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
889,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
890,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
891,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
892,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
893,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
894,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,2.0,1.0,,,,,,,Surgery,Not evaluable,,,,,Not significant,Female,,,Intravenously,,Peptide
895,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
896,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
897,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
898,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
899,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
900,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
901,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
902,,,,,,,,,,,,,,,4.0,100000.0,,,64.0,,,,,Melanoma,,2.0,1.0,,,,,,,Surgery,Stable Desease,,,,,Not significant,Male,,,Intravenously,,Peptide
903,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
904,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
905,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
906,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
907,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
908,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
909,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
910,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
911,,,,,,,,,,,,,,,4.0,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,2.0,1.0,,,,,,,Surgery,Stable Desease,,,,,Not significant,Female,,,Intravenously,,Peptide
912,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
913,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
914,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
915,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,2.0,1.0,,,,,,,Surgery,Not evaluable,,,,,Not significant,Female,,,Intravenously,,Peptide
916,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
917,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
918,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
919,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
920,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
921,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
922,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
923,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
924,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
925,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
926,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
927,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
928,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
929,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
930,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
931,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
932,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
933,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
934,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
935,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
936,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
937,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
938,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
939,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
940,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
941,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
942,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
943,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
944,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
945,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
946,,,,,,,,,,,,,,,4.0,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,2.0,1.0,,,,,,,Surgery,Stable Desease,,,,,Not significant,Female,,,Intravenously,,Peptide
947,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
948,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
949,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
950,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
951,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
952,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
953,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
954,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
955,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
956,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
957,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
958,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
959,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
960,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
961,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
962,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
963,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
964,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
965,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
966,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
967,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
968,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
969,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
970,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
971,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
972,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
973,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
974,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
975,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
976,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
977,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
978,,,,,,,,,,,,,,,,2000000.0,,,51.0,,,,,Pancreatic cancer,,,,,,,,,,Immunotherapy,Not evaluable,,,,,,Male,,,,,
979,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
980,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
981,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
982,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
983,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
984,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
985,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
986,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
987,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
988,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
989,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
990,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
991,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
992,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
993,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
994,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
995,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
996,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
997,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
998,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
999,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1000,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1001,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1002,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1003,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1004,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1005,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1006,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1007,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1008,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1009,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1010,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1011,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1012,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1013,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1014,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1015,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1016,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1017,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1018,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1019,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1020,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1021,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1022,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1023,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1024,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1025,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1026,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1027,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1028,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1029,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1030,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1031,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1032,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1033,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1034,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1035,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1036,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1037,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1038,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1039,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1040,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1041,,,,,,,,,,,,,,,,2000000.0,,,39.0,,,,,Pancreatic cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1042,,,,,,,,,,,,,,,4.0,100000.0,,,61.0,,,,,Colon cancer,,2.0,1.0,,,,,,,Surgery,Partial Response,,,,,Not significant,Male,,,Intravenously,,Peptide
1043,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1044,,,,,,,,,,,,,,,4.0,500000.0,,,53.0,,,,,Breast cancer,,,,,,,,,,Surgery,Not evaluable,,,,,,Female,,,,,
1045,,,,,,,,,,,,,,,,100000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1046,,,,,,,,,,,,,,,,2000000.0,,,64.0,,,,,Melanoma,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1047,,,,,,,,,,,,,,,,100000.0,,,27.0,,,,,Hepatocellular carcinoma,,,,,,,,,,Surgery,Stable Desease,,,,,,Female,,,,,
1048,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1049,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1050,,,,,,,,,,,,,,,4.0,100000.0,,,61.0,,,,,Colon cancer,,2.0,1.0,,,,,,,Surgery,Partial Response,,,,,Not significant,Male,,,Intravenously,,Peptide
1051,,,,,,,,,,,,,,,,100000.0,,,61.0,,,,,Colon cancer,,,,,,,,,,Surgery,Partial Response,,,,,,Male,,,,,
1052,-,Not done,,,-,Not done,,,,,,,,,2.0,33000000.0,,,49.0,,,,,Melanoma,,,,,,,,,,Surgery,Not applicable,,,,,Not applicable,Female,,,Subcutaneously,IV,-
1053,-,Yes,,,-,Yes,,,,,,,,,4.0,22000000.0,,,81.0,,,,,Melanoma,,,,,,,,,,Surgery,Progressive Disease,,,,,,Female,,,,IV,
1054,-,Yes,,,-,Yes,,,,,,,,,4.0,40000000.0,,,39.0,,,,,Melanoma,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1055,-,Yes,,,-,Not done,,,,,,,,,4.0,44000000.0,,,50.0,,,,,Solid malignancies,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1056,-,Yes,,,,,,,,,,,,,4.0,40000000.0,,,71.0,,,,,Melanoma,,,,,,,,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1057,-,Yes,,,,,,,,,,,,,3.0,37000000.0,,,60.0,,,,,Thyroid Cancer,,,,,,,,,,Surgery,,,,,,,Male,,,,II,
1058,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1059,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1060,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1061,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1062,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1063,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1064,,,,,,,,,,,,,,,4.0,,61.0,18.0,51.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,Chemotherapy,,II,
1065,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1066,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1067,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1068,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1069,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1070,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1071,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1072,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1073,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1074,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1075,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1076,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1077,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1078,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1079,,,,,,,,,,,,,,,,,61.0,18.0,51.0,,,,,,,,,,,,,,,,,,,,,,,,Chemotherapy,,III,
1080,,,,,,,,,,,,,,,,,61.0,18.0,51.0,,,,,,,,,,,,,,,,,,,,,,,,Chemotherapy,,III,
1081,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1082,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1083,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1084,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1085,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1086,,,,,,,,,,,,,,,,,61.0,18.0,51.0,,,,,,,,,,,,,,,,,,,,,,,,Chemotherapy,,III,
1087,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1088,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1089,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1090,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1091,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1092,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1093,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1094,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1095,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1096,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1097,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1098,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1099,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1100,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1101,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1102,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1103,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1104,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1105,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1106,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1107,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1108,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1109,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1110,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1111,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1112,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1113,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1114,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1115,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1116,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1117,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1118,,,,,,,,,,,,,,,,,61.0,18.0,51.0,,,,,,,,,,,,,,,,,,,,,,,,Chemotherapy,,III,
1119,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1120,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1121,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1122,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1123,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1124,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1125,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1126,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1127,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1128,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1129,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1130,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1131,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1132,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1133,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1134,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1135,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1136,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1137,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1138,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1139,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1140,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1141,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1142,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1143,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1144,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1145,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1146,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1147,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1148,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1149,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1150,,,,,Tumor antigen,Yes,,,,,,,,,4.0,,,,,,,,HLA-A2,Ovarian cancer,,2.0,1.0,,,,,Microorganisms and their fragments,Monocytes,Surgery,,,,,,Not significant,,,Immunotherapy,Intradermal,,Peptide
1151,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1152,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1153,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1154,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1155,,,,,,,,,,,,,,,4.0,,,,61.0,,,,,,,,,,,,,,,Chemotherapy,Complete response,,,,,,,,,,I,
1156,,,,,-,No,,,,,,,,,2.0,50000000.0,,,62.0,,,,,Renal cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
1157,,,,,,,,,,,,,,,2.0,50000000.0,,,56.0,,,,,Renal cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
1158,,,,,,,,,,,,,,,3.0,50000000.0,,,67.0,,,,,Renal cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,IV,
1159,,,,,,,,,,,,,,,2.0,50000000.0,,,29.0,,,,,Renal cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,II,
1160,,,,,,,,,,,,,,,2.0,50000000.0,,,24.0,,,,,Renal cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,IV,
1161,,,,,,,,,,,,,,,2.0,50000000.0,,,62.0,,,,,Renal cancer,,,,,,,,,,,,,,,,,Male,,,,IV,
1162,,,,,,,,,,,,,,,2.0,50000000.0,,,43.0,,,,,Breast cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,IV,
1163,,,,,,,,,,,,,,,2.0,50000000.0,,,29.0,,,,,Breast cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,IV,
1164,,,,,,,,,,,,,,,2.0,50000000.0,,,59.0,,,,,Breast cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,II,
1165,,,,,,,,,,,,,,,2.0,50000000.0,,,66.0,,,,,Breast cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,II,
1166,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1167,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1168,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1169,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1170,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1171,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1172,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1173,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1174,,,,,,,,,,,,,,,,,,,60.0,Years,Live,5.0,,,,,,,,,,,,,,,,,,,Male,,,,I,
1175,,,,,,,,,,,,,,,,1000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,Chemotherapy,Progressive Disease,,,,,,,,,,IV,Peptide
1176,,,,,,,,,,,,,,,,1000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,Chemotherapy,Progressive Disease,,,,,,,,,,IV,Peptide
1177,,,,,,,,,,,,,,,,1000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,Radiotherapy,,,,,,,,,,,IV,Peptide
1178,,,,,,,,,,,,,,,,1000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,,,,,,,,,,,,IV,Peptide
1179,,,,,,,,,,,,,,,,1000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,Surgery,Progressive Disease,,,,,,,,,,IV,Peptide
1180,,,,,,,,,,,,,,,,5000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,Chemotherapy,Not evaluable,,,,,,,,,,IV,Peptide
1181,,,,,,,,,,,,,,,,5000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,Chemotherapy,Progressive Disease,,,,,,,,,,IV,Peptide
1182,,,,,,,,,,,,,,,,5000000.0,,,,,,,,Hepatocellular carcinoma,,,,,,,,Microorganisms and their fragments,Monocytes,Chemotherapy,Progressive Disease,,,,,,,,,,IV,Peptide
1183,,,,,,,,,,,,,,,4.0,6.0,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Male,,,,IV,
1184,,,,,,,,,,,,,,,4.0,6.0,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Male,,,,IV,
1185,,,,,,,,,,,,,,,4.0,6.0,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Male,,,,IV,
1186,,,,,,,,,,,,,,,4.0,6.0,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Male,,,,IV,
1187,,,,,,,,,,,,,,,4.0,6.0,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Male,,,,IV,
1188,,,,,,,,,,,,,,,4.0,6.0,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Male,,,,IV,
1189,,,,,,,,,,,,,,,4.0,6.0,,,59.0,,,,,,,,,,,,,,,Surgery,Progressive Disease,,,,,None,Male,,,,IV,
1190,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,-,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1191,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,-,7.75,,,,,,1.0,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,,
1192,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,-,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1193,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,-,7.75,,,,,,1.0,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,,
1194,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,-,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1195,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,-,7.75,,,,,,1.0,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,,
1196,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,-,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1197,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,-,7.75,,,,,,1.0,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,,
1198,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,-,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1199,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,-,7.75,,,,,,1.0,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,,
1200,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,-,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1201,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,-,7.75,,,,,,1.0,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,,
1202,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,-,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1203,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,-,7.75,,,,,,1.0,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,,
1204,,,,,,,,,,,,,,,5.0,24970000.0,,,46.0,Months,-,12.54,,,,,,1.0,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1205,,,,,,,,,,,,,,,5.0,24100000.0,,,47.0,Months,-,7.75,,,,,,1.0,,,,,,Chemotherapy,Progressive Disease,,,,,,Male,,,,,
1206,,,,,,,,,,,,,,25000000.0,10.0,,,,18.0,Weeks,-,204.0,,Glioma,,,,,,,90.0,,,,,,,,,Not significant,Female,,,,,
1207,,,,,,,,,,,,,,11000000.0,10.0,,,,38.0,Weeks,-,305.0,,Glioma,,,,,,,90.0,,,,,,,,,Not significant,Male,,,,,
1208,,,,,,,,,,,,,,21000000.0,8.0,,,,60.0,Weeks,-,48.0,,Glioma,,,,,,,80.0,,,,,,,,,Not significant,Male,,,,,
1209,,,,,,,,,,,,,,25000000.0,10.0,,,,24.0,Weeks,-,47.0,,Glioma,,,,,,,80.0,,,,,,,,,Not significant,Male,,,,,
1210,,,,,,,,,,,,,,50000000.0,10.0,,,,23.0,Weeks,-,286.0,,Glioma,,,,,,,90.0,,,,,,,,,Not significant,Male,,,,,
1211,,,,,,,,,,,,,,58000000.0,10.0,,,,50.0,Weeks,-,90.0,,Glioma,,,,,,,90.0,,,,,,,,,Not significant,Female,,,,,
1212,,,,,,,,,,,,,,30000000.0,10.0,,,,61.0,Weeks,-,89.0,,Glioma,,,,,,,90.0,,,,,,,,,Not significant,Female,,,,,
1213,,,,,,,,,,,,,,10000000.0,10.0,,,,41.0,Weeks,-,281.0,,Myeloma,,,,,,,80.0,,,,,,,,,Not significant,Male,,,,,
1214,,,,,,,,,,,,,,35000000.0,10.0,,,,25.0,Weeks,-,182.0,,Adrenal cortical carcinoma,,,,,,,90.0,,,,,,,,,Not significant,Female,,,,,
1215,,,,,,,,,,,,,,42000000.0,10.0,,,,45.0,Weeks,-,45.0,,Glioma,,,,,,,90.0,,,,,,,,,Not significant,Female,,,,,
1216,,,,,,,,,,,,,,38000000.0,6.0,,,,60.0,Weeks,-,44.0,,Glioma,,,,,,,90.0,,,,,,,,,None,Female,,,,,
1217,,,,,,,,,,,,,,25000000.0,10.0,,,,42.0,Weeks,-,45.0,,Myeloma,,,,,,,70.0,,,,,,,,,Not significant,Female,,,,,
1218,,,,,,,,,,,,,,23000000.0,6.0,,,,34.0,Weeks,-,23.0,,Glioma,,,,,,,90.0,,,,,,,,,Not significant,Female,,,,,
1219,,,,,,,,,,,,,,30000000.0,10.0,,,,55.0,Weeks,-,121.0,,Glioma,,,,,,,70.0,,,,,,,,,Not significant,Female,,,,,
1220,,,,,,,,,,,,,,61000000.0,10.0,,,,69.0,Weeks,-,61.0,,Glioma,,,,,,,70.0,,,,,,,,,None,Male,,,,,
1221,,,,,,,,,,,,,,61000000.0,10.0,,,,47.0,Weeks,-,155.0,,Glioma,,,,,,,80.0,,,,,,,,,None,Male,,,,,
1222,,,,,,,,,,,,,,25000000.0,10.0,,,,18.0,Weeks,-,204.0,,Glioma,,,,,,,90.0,,,,,,,,,Not significant,Female,,,,,
1223,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1224,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1225,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1226,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1227,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1228,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1229,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1230,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1231,Tumor antigen,Yes,,,,,,,,,,,,1.0,12.0,,,,69.0,,,,HLA-A*2402,Glioblastoma,,,,,,,1.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1232,,,,,,,,,,,,,,,,,,,65.0,,,,,,,,,,,,,,,Target therapy,Progressive Disease,Increase,23.0,56.0,AFP,,Male,,,,III,
1233,,,,,,,,,,,,,,,,,,,65.0,,,,,,,,,,,,,,,Target therapy,Progressive Disease,Increase,23.0,56.0,AFP,,Male,,,,III,
1234,,,,,,,,,,,,,,,,,,,65.0,,,,,,,,,,,,,,,Target therapy,Progressive Disease,Increase,23.0,56.0,AFP,,Male,,,,III,
1235,,,,,,,,,,,,,,,,,,,65.0,,,,,,,,,,,,,,,Target therapy,Progressive Disease,Increase,23.0,56.0,AFP,,Male,,,,III,
1236,,,,,,,,,,,,,,,,,,,65.0,,,,,,,,,,,,,,,Target therapy,Progressive Disease,Increase,23.0,56.0,AFP,,Male,,,,III,
1237,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1238,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1239,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1240,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1241,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1242,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1243,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1244,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1245,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1246,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1247,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1248,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1249,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1250,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1251,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1252,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1253,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1254,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1255,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1256,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1257,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1258,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1259,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1260,Tumor antigen,Yes,,,,,,,,,,,,10000000.0,10.0,40000000.0,,,53.0,-,Live,7.0,HLA-A*2402,,,,,,,,,,,,Stable Desease,,,,,Not significant,Female,,,,,
1261,-,No,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1262,-,No,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1263,-,No,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1264,-,No,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1265,-,No,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1266,-,No,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1267,-,No,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1268,-,No,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1269,-,No,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1270,-,No,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1271,-,No,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1272,-,No,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1273,-,No,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1274,-,No,,,,,,,,,,,,,1.0,,,,90.0,Weeks,Dead,18.0,,,,,,,,,70.0,,,,Progressive Disease,,,,,None,Female,,,,,
1275,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1276,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1277,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1278,,,,,,,,,,,,,,,5.0,,,,46.0,Months,-,33.0,,,,,,,,,1.0,,,Chemotherapy,Complete response,,,,,,Male,,,,IV,
1279,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1280,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1281,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1282,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1283,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1284,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1285,,,,,,,,,,,,,,,5.0,,,,46.0,Months,-,33.0,,,,,,,,,1.0,,,Chemotherapy,Complete response,,,,,,Male,,,,IV,
1286,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1287,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1288,,,,,,,,,,,,,,,5.0,,,,46.0,Months,-,33.0,,,,,,,,,1.0,,,Chemotherapy,Complete response,,,,,,Male,,,,IV,
1289,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1290,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1291,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1292,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1293,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,14.4,,,,,,,,,1.0,,,Immunotherapy,Stable Desease,,,,,,Male,,,,IV,
1294,,,,,,,,,,,,,,,4.0,,,,,Months,Dead,28.0,,Melanoma,,,,,,,,,Monocytes,,Partial Response,,,,,Not significant,,,,Intravenously,,RNA
1295,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1296,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1297,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1298,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1299,,,,,,,,,,,,,,,3.0,,,,,Months,Dead,28.0,,Melanoma,,,,,,,,,Monocytes,,,,,,,Not significant,,,,Intravenously,,RNA
1300,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1301,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1302,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1303,,,,,,,,,,,,,,,5.0,,,,,Months,Live,14.0,,Melanoma,,,,,,,,,Monocytes,,Partial Response,,,,,Not significant,,,,Intravenously,,RNA
1304,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,14.4,,,,,,,,,1.0,,,Immunotherapy,Stable Desease,,,,,,Male,,,,IV,
1305,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1306,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1307,,,,,,,,,,,,,,,5.0,,,,46.0,Months,-,33.0,,,,,,,,,1.0,,,Chemotherapy,Complete response,,,,,,Male,,,,IV,
1308,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1309,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1310,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1311,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1312,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1313,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1314,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1315,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1316,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1317,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1318,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1319,,,,,,,,,,,,,,,4.0,,,,,Months,Dead,28.0,,Melanoma,,,,,,,,,Monocytes,,Stable Desease,,,,,Not significant,,,,Intravenously,,RNA
1320,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1321,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1322,,,,,,,,,,,,,,,5.0,,,,46.0,Months,-,33.0,,,,,,,,,1.0,,,Chemotherapy,Complete response,,,,,,Male,,,,IV,
1323,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1324,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1325,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1326,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1327,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1328,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1329,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1330,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1331,,,,,,,,,,,,,,,5.0,,,,46.0,Months,-,33.0,,,,,,,,,1.0,,,Chemotherapy,Complete response,,,,,,Male,,,,IV,
1332,,,,,,,,,,,,,,,5.0,,,,,Months,Dead,28.0,,Melanoma,,,,,,,,,Monocytes,,Complete response,,,,,Not significant,,,,Intravenously,,RNA
1333,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1334,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1335,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1336,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1337,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1338,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1339,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1340,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1341,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1342,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1343,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1344,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1345,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1346,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1347,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1348,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1349,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1350,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1351,,,,,,,,,,,,,,,5.0,,,,51.0,Months,-,34.1,,,,,,,,,1.0,,,Chemotherapy,Partial Response,,,,,,Female,,,,IV,
1352,,,,,,,,,,,,,,,5.0,,,,,Months,Dead,28.0,,Melanoma,,,,,,,,,Monocytes,,,,,,,Not significant,,,,Intravenously,,RNA
1353,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1354,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1355,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1356,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1357,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1358,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1359,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1360,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1361,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1362,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1363,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1364,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1365,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1366,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1367,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1368,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1369,,,,,,,,,,,,,,,5.0,,,,,Months,Live,14.0,,Melanoma,,,,,,,,,Monocytes,,,,,,,Not significant,,,,Intravenously,,RNA
1370,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1371,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1372,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1373,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1374,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1375,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1376,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1377,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1378,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1379,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1380,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1381,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1382,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1383,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1384,,,,,,,,,,,,,,,5.0,,,,,Months,Dead,28.0,,Melanoma,,,,,,,,,Monocytes,,,,,,,Not significant,,,,Intravenously,,RNA
1385,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1386,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1387,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1388,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1389,,,,,,,,,,,,,,,4.0,,,,42.0,Months,-,8.6,,,,,,,,,1.0,,,Chemotherapy,Progressive Disease,,,,,,Female,,,,IV,
1390,,,,,,,,,,,,,,,5.0,,,,46.0,Months,-,33.0,,,,,,,,,1.0,,,Chemotherapy,Complete response,,,,,,Male,,,,IV,
1391,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1392,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1393,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1394,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1395,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1396,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1397,,,,,,,,,,,,,,,5.0,,,,46.0,Months,-,33.0,,,,,,,,,1.0,,,Chemotherapy,Complete response,,,,,,Male,,,,IV,
1398,,,,,,,,,,,,,,,5.0,,,,42.0,Months,-,18.8,,,,,,,,,1.0,,,Chemotherapy,Stable Desease,,,,,,Female,,,,IV,
1399,,,,,,,,,,,,,,,4.0,,,,41.0,Months,-,9.9,,,,,,,,,2.0,,,Surgery,Progressive Disease,,,,,,Male,,,,IV,
1400,,,,,,,,,,,,,,,5.0,,,,59.0,Days,Dead,95.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1401,,,,,,,,,,,,,,,5.0,,,,64.0,Days,Dead,157.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Peptide
1402,,,,,,,,,,,,,,,3.0,,,,63.0,Days,Dead,72.0,,Colon cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Peptide
1403,,,,,,,,,,,,,,,6.0,,,,38.0,Days,Live,397.0,,Fibrosarcoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1404,,,,,,,,,,,,,,,3.0,,,,31.0,Days,Dead,81.0,,Ovarian cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Peptide
1405,,,,,,,,,,,,,,,4.0,,,,56.0,Days,Dead,117.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Peptide
1406,,,,,,,,,,,,,,,4.0,,,,50.0,Days,Dead,74.0,,Cervical cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Peptide
1407,,,,,,,,,,,,,,,6.0,,,,69.0,Days,Live,342.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1408,,,,,,,,,,,,,,,4.0,,,,62.0,Days,Dead,184.0,,Lung cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1409,,,,,,,,,,,,,,,4.0,,,,70.0,Days,Dead,116.0,,Colon cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1410,,,,,,,,,,,,,,,6.0,,,,51.0,Days,Dead,136.0,,Breast cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Lysate
1411,,,,,,,,,,,,,,,3.0,,,,59.0,Days,Dead,149.0,,Prostate cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1412,,,,,,,,,,,,,,,4.0,,,,70.0,Days,Dead,123.0,,Cholangiocellular carcinoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Peptide
1413,,,,,,,,,,,,,,,6.0,,,,71.0,Days,Dead,171.0,,Colon cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1414,,,,,,,,,,,,,,,6.0,,,,66.0,Days,Dead,173.0,,Ovarian cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,Peptide
1415,,,,,,,,,,,,,,,6.0,,,,55.0,Days,Dead,315.0,,Prostate cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1416,,,,,,,,,,,,,,,6.0,,,,57.0,Days,Dead,152.0,,Fibrosarcoma,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Peptide
1417,,,,,,,,,,,,,,,6.0,,,,54.0,Days,Dead,198.0,,Ovarian cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Peptide
1418,,,,,,,,,,,,,,,5.0,,,,51.0,Days,Dead,176.0,,Ovarian cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Peptide
1419,,,,,,,,,,,,,,,6.0,,,,67.0,Days,Dead,356.0,,Prostate cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,Lysate
1420,,,,,,,,,,,,,,,6.0,,,,62.0,Days,Dead,207.0,,Melanoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Peptide
1421,,,,,,,,,,,,,,,6.0,,,,70.0,Days,Live,450.0,,Fibrosarcoma,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Lysate
1422,,,,,,,,,,,,,,,6.0,,,,40.0,Days,Live,528.0,,Lung cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,Peptide
1423,,,,,,,,,,,,,,,6.0,,,,42.0,Days,Live,454.0,,Ovarian cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Lysate
1424,,,,,,,,,,,,,,,6.0,,,,73.0,Days,Live,458.0,,Prostate cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,Lysate
1425,,,,,,,,,,,,,,,4.0,,,,36.0,Days,Dead,87.0,,Colon cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,Peptide
1426,,,,,,,,,,,,,,,5.0,,,,60.0,Days,Live,498.0,,Ovarian cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,Peptide
1427,,,,,,,,,,,,,,,6.0,,,,60.0,Days,Live,462.0,,Ovarian cancer,,,,,,,,,,,Partial Response,,,,,,Female,,,,,Lysate
1428,,,,,,,,,,,,,,,6.0,,,,68.0,Days,Live,463.0,,Prostate cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,Lysate
1429,,,,,,,,,,,,,,,5.0,,,,42.0,Days,Dead,246.0,,Cervical cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Peptide
1430,,,,,,,,,,,,,,,6.0,,,,56.0,Days,Dead,193.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Peptide
1431,,,,,,,,,,,,,,,6.0,,,,61.0,Days,Live,493.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Peptide
1432,,,,,,,,,,,,,,,6.0,,,,33.0,Days,Live,485.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Peptide
1433,,,,,,,,,,,,,,,6.0,,,,38.0,Days,Live,451.0,,Breast cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Peptide
1434,,,,,,,,,,,,,,,6.0,,,,57.0,Days,Dead,417.0,,Lung cancer,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,Lysate
1435,,,,,,,,,,,,,,,6.0,,,,54.0,Days,Live,383.0,,Cervical cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,Lysate
1436,,,,,,,,,,,,,,,2.0,,,,54.0,Days,Live,397.0,,Renal cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Peptide
1437,,,,,,,,,,,,,,,3.0,,,,54.0,Days,Dead,439.0,,Colon cancer,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,Peptide
1438,,,,,,,,,,,,,,,5.0,,,,59.0,Days,Dead,95.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1439,,,,,,,,,,,,,,,5.0,,,,64.0,Days,Dead,157.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Peptide
1440,,,,,,,,,,,,,,,3.0,,,,63.0,Days,Dead,72.0,,Colon cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Peptide
1441,,,,,,,,,,,,,,,6.0,,,,38.0,Days,Live,397.0,,Fibrosarcoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1442,,,,,,,,,,,,,,,3.0,,,,31.0,Days,Dead,81.0,,Ovarian cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Peptide
1443,,,,,,,,,,,,,,,4.0,,,,56.0,Days,Dead,117.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Peptide
1444,,,,,,,,,,,,,,,4.0,,,,50.0,Days,Dead,74.0,,Cervical cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Peptide
1445,,,,,,,,,,,,,,,6.0,,,,69.0,Days,Live,342.0,,Head and neck,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1446,,,,,,,,,,,,,,,4.0,,,,62.0,Days,Dead,184.0,,Lung cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1447,,,,,,,,,,,,,,,4.0,,,,70.0,Days,Dead,116.0,,Colon cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1448,,,,,,,,,,,,,,,6.0,,,,51.0,Days,Dead,136.0,,Breast cancer,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,Lysate
1449,,,,,,,,,,,,,,,3.0,,,,59.0,Days,Dead,149.0,,Prostate cancer,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Lysate
1450,,,,,,,,,,,,,,,4.0,,,,70.0,Days,Dead,123.0,,Cholangiocellular carcinoma,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,Peptide
1451,,,,,,,,,,,,,,,,4500000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,IV,Peptide
1452,,,,,,,,,,,,,,,4.0,8900000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,,Peptide
1453,,,,,,,,,,,,,,,3.0,9500000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,IV,Peptide
1454,,,,,,,,,,,,,,,,4700000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1455,,,,,,,,,,,,,,,,10600000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Male,,Immunotherapy,Intravenously,III,Peptide
1456,,,,,,,,,,,,,,,,11.2,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,,Peptide
1457,,,,,,,,,,,,,,,,6.5,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,IV,Peptide
1458,,,,,,,,,,,,,,,,6.9,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,,Peptide
1459,,,,,,,,,,,,,,,,9.4,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,,Peptide
1460,,,,,,,,,,,,,,,3.0,5.2,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,,Peptide
1461,,,,,,,,,,,,,,,,10.7,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,,Peptide
1462,,,,,,,,,,,,,,,,8.9,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,,Peptide
1463,,,,,,,,,,,,,,,4.0,12.1,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,IV,Peptide
1464,,,,,,,,,,,,,,,3.0,4.8,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,IV,Peptide
1465,,,,,,,,,,,,,,,3.0,4.8,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,,Peptide
1466,,,,,,,,,,,,,,,,7.9,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1467,,,,,,,,,,,,,,,,12.5,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1468,,,,,,,,,,,,,,,,5.1,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Peptide
1469,,,,,,,,,,,,,,,4.0,5.6,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1470,,,,,,,,,,,,,,,3.0,4.3,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1471,,,,,,,,,,,,,,,,7.8,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,,Peptide
1472,,,,,,,,,,,,,,,3.0,6.5,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,III,Peptide
1473,,,,,,,,,,,,,,,3.0,11.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,,Peptide
1474,,,,,,,,,,,,,,,,9.8,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,,Peptide
1475,,,,,,,,,,,,,,,,10.2,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,III,Peptide
1476,,,,,,,,,,,,,,,3.0,7.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1477,,,,,,,,,,,,,,,4.0,4.9,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,III,Peptide
1478,,,,,,,,,,,,,,,,4500000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,,Peptide
1479,,,,,,,,,,,,,,,3.0,8900000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1480,,,,,,,,,,,,,,,,9500000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Male,,Immunotherapy,Intravenously,III,Peptide
1481,,,,,,,,,,,,,,,3.0,4700000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1482,,,,,,,,,,,,,,,4.0,10600000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,IV,Peptide
1483,,,,,,,,,,,,,,,3.0,11.2,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,IV,Peptide
1484,,,,,,,,,,,,,,,,6.5,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,III,Peptide
1485,,,,,,,,,,,,,,,,6.9,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,III,Peptide
1486,,,,,,,,,,,,,,,,9.4,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,III,Peptide
1487,,,,,,,,,,,,,,,,5.2,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Male,,Immunotherapy,Intravenously,III,Peptide
1488,,,,,,,,,,,,,,,,10.7,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1489,,,,,,,,,,,,,,,4.0,8.9,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1490,,,,,,,,,,,,,,,3.0,12.1,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Male,,Immunotherapy,Intravenously,,Peptide
1491,,,,,,,,,,,,,,,,4.8,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,IV,Peptide
1492,,,,,,,,,,,,,,,,4.8,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1493,,,,,,,,,,,,,,,3.0,7.9,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Male,,Immunotherapy,Intravenously,III,Peptide
1494,,,,,,,,,,,,,,,,12.5,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,IV,Peptide
1495,,,,,,,,,,,,,,,3.0,5.1,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1496,,,,,,,,,,,,,,,,5.6,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,III,Peptide
1497,,,,,,,,,,,,,,,,4.3,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,IV,Peptide
1498,,,,,,,,,,,,,,,,7.8,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,,Peptide
1499,,,,,,,,,,,,,,,4.0,6.5,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,,Peptide
1500,,,,,,,,,,,,,,,3.0,11.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,IV,Peptide
1501,,,,,,,,,,,,,,,3.0,9.8,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1502,,,,,,,,,,,,,,,4.0,10.2,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1503,,,,,,,,,,,,,,,3.0,7.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,III,Peptide
1504,,,,,,,,,,,,,,,,4.9,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,,Peptide
1505,,,,,,,,,,,,,,,4.0,4500000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1506,,,,,,,,,,,,,,,,8900000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1507,,,,,,,,,,,,,,,,9500000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,,Peptide
1508,,,,,,,,,,,,,,,,4700000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,IV,Peptide
1509,,,,,,,,,,,,,,,3.0,10600000.0,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,Female,,Immunotherapy,Intravenously,III,Peptide
1510,,,,,,,,,,,,,,,3.0,11.2,72.0,43.0,51.0,Months,Live,13.0,HLA-A2,Lung cancer,,2.0,0.0,,,,,,Monocytes,Not done,,,,,,Not significant,,,Immunotherapy,Intravenously,IV,Peptide
1511,,,,,,,,,,,,,,,1.0,,,,,Months,Live,20.0,,,,,,,,,,,,Chemotherapy,Progressive Disease,,,,,None,Female,,,,,
1512,,,,,,,,,,,,,,,1.0,,,,,Months,-,20.0,,,,,,,,,,,,Not done,Progressive Disease,,,,,Not significant,Male,,,,,
1513,,,,,,,,,,,,,,,1.0,,,,,Months,-,20.0,,,,,,,,,,,,Not done,Partial Response,,,,,Not significant,Male,,,,,
1514,,,,,,,,,,,,,,,2.0,,,,,Months,-,19.0,,,,,,,,,,,,,Stable Desease,,,,,Not significant,Male,,,,,
1515,,,,,,,,,,,,,,,6.0,,,,,Months,-,19.0,,,,,,,,,,,,,Partial Response,,,,,Not significant,Male,,,,,
1516,,,,,,,,,,-,No,,,20000000.0,4.0,,,,51.0,Months,-,18.0,,Renal cancer,Normal,1.0,1.0,,,,,TNF-α,Monocytes,,Stable Desease,,,,,Not significant,Male,,Immunotherapy,Subcutaneously,,
1517,,,,,,,,,,,,,,,1.0,,,,,Months,-,17.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
1518,,,,,,,,,,-,No,,,20000000.0,4.0,,,,51.0,Months,-,18.0,,Renal cancer,Normal,1.0,1.0,,,,,TNF-α,Monocytes,,Partial Response,,,,,Not significant,Male,,Immunotherapy,Subcutaneously,,
1519,,,,,,,,,,,,,,,2.0,,,,,Months,-,21.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
1520,,,,,,,,,,,,,,,3.0,,,,,Months,-,16.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
1521,,,,,,,,,,,,,,,1.0,,,,,Months,-,16.0,,,,,,,,,,,,,Partial Response,,,,,,Male,,,,,
1522,,,,,,,,,,,,,,,1.0,,,,,Months,-,15.0,,,,,,,,,,,,,Progressive Disease,,,,,Not significant,Male,,,,,
1523,,,,,,,,,,,,,,,1.0,,,,,Months,-,10.0,,,,,,,,,,,,,Complete response,,,,,,Male,,,,,
1524,,,,,,,,,,,,,,,1.0,,,,,Months,-,10.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
1525,,,,,,,,,,,,,,,3.0,,,,,Months,-,9.0,,,,,,,,,,,,,Partial Response,,,,,,Male,,,,,
1526,,,,,,,,,,,,,,,3.0,,,,,Months,-,10.0,,,,,,,,,,,,,Complete response,,,,,,Male,,,,,
1527,,,,,,,,,,,,,,,1.0,,,,,Months,-,15.0,,,,,,,,,,,,,Complete response,,,,,,Male,,,,,
1528,,,,,,,,,,,,,,,1.0,,,,,Months,-,12.0,,,,,,,,,,,,,Progressive Disease,,,,,,Male,,,,,
1529,,,,,,,,,,,,,,,1.0,,,,,Months,-,21.0,,,,,,,,,,,,,Partial Response,,,,,,Male,,,,,
1530,,,,,,,,,,,,,,,1.0,,,,,Months,-,15.0,,,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,
1531,,,,,,,,,,,,,,,2.0,,,,,Months,-,16.0,,,,,,,,,,,,,Progressive Disease,,,,,,Female,,,,,
1532,,,,,,,,,,,,,,,2.0,,,,,Months,-,20.0,,,,,,,,,,,,Surgery,Complete response,,,,,,Male,,,,,
1533,,,,,,,,,,,,,,,3.0,,,,,Months,-,6.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
1534,,,,,,,,,,,,,,,1.0,,,,,Months,Dead,4.0,,,,,,,,,,,,,Death,,,,,,Female,,,,,
1535,,,,,,,,,,,,,,,3.0,,,,,Months,-,6.0,,,,,,,,,,,,Chemotherapy,Partial Response,,,,,,Male,,,,,
1536,,,,,,,,,,,,,,,2.0,,,,,Months,-,11.0,,,,,,,,,,,,,Stable Desease,,,,,,Female,,,,,
1537,,,,,,,,,,,,,,,2.0,,,,,Months,-,5.0,,,,,,,,,,,,,Stable Desease,,,,,,Male,,,,,
1538,,,,,,,,,,,,,,,2.0,,,,,Months,-,5.0,,,,,,,,,,,,Surgery,Stable Desease,,,,,,Male,,,,,
1539,,,,,,,,,,,,,,,,,,,66.0,,,,,,,,,,,,80.0,,,Surgery,,,,,,,Female,,,,,
1540,,,,,,,,,,,,,,,,,,,59.0,,,,,,,,,,,,80.0,,,Surgery,,,,,,,Female,,,,,
1541,,,,,,,,,,,,,,,,,,,66.0,,,,,,,,,,,,70.0,,,Surgery,,,,,,,Female,,,,,
1542,,,,,,,,,,,,,,,,,,,66.0,,,,,,,,,,,,80.0,,,Surgery,,,,,,,Male,,,,,
1543,,,,,,,,,,,,,,,,,,,78.0,,,,,,,,,,,,70.0,,,Surgery,,,,,,,Male,,,,,
1544,,,,,,,,,,,,,,,,,,,54.0,,,,,,,,,,,,80.0,,,Surgery,,,,,,,Female,,,,,
1545,,,,,,,,,,,,,,,,,,,61.0,,,,,,,,,,,,90.0,,,Surgery,,,,,,,Female,,,,,
1546,,,,,,,,,,,,,,,,,,,57.0,,,,,,,,,,,,70.0,,,Surgery,,,,,,,Male,,,,,
1547,,,,,,,,,,,,,,,,,,,48.0,,,,,,,,,,,,90.0,,,Surgery,,,,,,,Male,,,,,
1548,,,,,,,,,,,,,,,,,,,59.0,,,,,,,,,,,,90.0,,,Surgery,,,,,,,Male,,,,,
